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CHAPTER I 
 
BACKGROUND AND OBJECTIVES 
 
The Era of Proteomics and Biomarkers Discovery 
 Proteomics encompasses the comprehensive identification and quantification of proteins 
specific to the physiological state of a cell, tissue or organism. The term “proteome” or 
“proteomics” was introduced in the  mid-1990’s, although proteomic strategies have been around 
for decades [1]. Instead of focusing on one particular protein, proteomic studies often take the 
approach of investigating hundreds or even thousands of proteins simultaneously in a single 
experiment by coupling newly developed proteomic strategies with modern mass spectrometers. 
[2-4].  
 Proteomic studies are complementary to genomic studies, although the proteome is far 
more complex than the genome for several reasons. First, one gene may result in multiple protein 
products due to gene splicing [5]. Second, posttranslational modifications are essential for protein 
structure and function, which cannot be fully predicted from the genome sequence [6]. Third, the 
proteome is highly dynamic in relative abundance and subcellular localization. All of these 
aspects should be considered when investigating the physiological state of a cell or tissue.  
 As a technology-driven science, proteomics has been accelerated by the advancement of 
various related research areas. First, the completions of the genomic sequences of human and 
other species have, in principle, provided the amino acid sequence of all the potentially encoded 
proteins for those species [7, 8]. The resulting genomic sequence databases have provided a 
library of amino acid sequence information that is required for proteomic study. Second, the 
development of modern mass spectrometry, especially matrix-assisted laser desorption/ionization 
(MALDI) and electrospray ionization (ESI) mass spectrometry [9, 10], has made it possible for 
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the ionization of nonvolatile, large analytes such as proteins without significant fragmentation. 
MALDI and ESI mass spectrometry have emerged as very important instrumentations for protein 
identification, posttranslational modification characterization, assessing protein expression 
pattern, solving protein-protein interaction and protein structure [11-13]. Third, the emergence 
and development of bioinformatics helps to integrate the vast amount of information obtained 
from genomic and proteomic studies to assemble comprehensive and biologically relevant 
molecular pathways. The data management, mining and interpretation for proteomic studies are 
made possible as a direct result of the advancement in bioinformatics [14, 15].  
 As a discovery-driven technology, the scope of proteomics extends beyond simple 
cataloguing of proteins within an organ to encompass detailed functional analysis of proteins. 
Proteomics approaches have been widely utilized to classify and elucidate mechanisms 
underlying various diseases, such as cancer, cardiovascular disease, and various neurological 
disorders [16-19]. A detailed understanding of proteins found to be differentially expressed in a 
disease-specific fashion would be expected to offer great insight into the understanding of 
specific pathogenic mechanisms, thereby providing diagnostic markers as well as potential drug 
targets. From this perspective, recently discovered protein markers derived from proteomic 
studies have been suggested as having the potential for diagnostic and prognostic applications in 
the areas of ovarian, lung and brain tumors [20-23]. 
 
Proteomics Technologies 
 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is one of the most 
widely used techniques for proteomic studies. It is a powerful protein separation technique which 
can resolve up to thousands of different protein species [24]. The protein mixtures are first 
separated according to their isoelectric point by isoelectric focusing and then separated according 
to their size by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The 
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separated proteins are visualized with different staining techniques, such coomassie blue staining. 
Differentially expressed proteins are identified by comparing spot intensity between samples. The 
gel spots of interested are excised and digested with a protease. From the digested peptides, the 
identities of these protein markers are characterized using peptide mapping or peptide sequence 
analysis using mass spectrometry. This technique, however, has some limitations. Very acidic or 
basic proteins, very large or small proteins, and membrane proteins are underrepresented in 2D 
PAGE pattern. The technique is also time consuming and requires a relatively large sample size, 
usually in the microgram range. The gel-to-gel variance can be significant but the introduction of 
two-dimensional difference gel electrophoresis (2-D DIGE) technology, which allows for the 
direct comparison of protein abundance changes across multiple samples simultaneously in one 
experiment, has minimized the gel-to-gel variation [25].  
 Liquid chromatography-based peptide separation coupled with tandem mass spectrometry 
offers another powerful technique for proteomic studies [2, 4]. In this approach, complex protein 
mixtures are directly digested and resulting peptides are separated over multiple liquid 
chromatographies based on different peptide physical properties. A commonly used approach is 
referred to as multidimensional protein identification technology (MudPIT). This approach 
involves separation by strong cation exchange chromatography followed by subsequent 
separation of each corresponding fraction with reverse phase chromatography using capillary 
HPLC [2, 26]. The separated peptides are directly introduced into the mass spectrometer after 
eluting off from the reversed phase column. The downstream tandem mass spectrometry is 
operated in a data-dependent acquisition mode.  Computer algorithms such as SEQUEST can 
then be used to determine the “best fit” between the MS/MS sequence information and the protein 
databases. In this way, more than one thousand proteins are identified within a single MudPIT 
experiment [27]. One limitation of these analyses is that they generally are qualitative while 
quantification analysis is critical for comparative proteomics. One possible solution to this is the 
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various labeling techniques that have been developed for semi-quantitative analysis using LC-
MS/MS, such as isotope-coded affinity tag (ICAT) technology [28]. The ICAT approach reduces 
the sample complexity by purifying only the cysteine-peptides and provides a promising tool for 
the relative quantification of low abundant proteins. It has been successfully applied to various 
comparative proteomic studies [29, 30].   
 
Direct Tissue Protein Profiling Using MALDI Mass Spectrometry 
  Direct tissue protein profiling and imaging using MALDI mass spectrometry has 
emerged as a valuable discovery tool to visualize specific proteins from intact tissue sections. 
Upon direct analysis of tissue sections cut from frozen tissue using MALDI MS, hundreds of 
peptides and proteins can be simultaneously detected and mapped [13, 31-33]. Matrix solution, 
such as sinapinic acid, is directly deposited onto tissue sections. The soluble proteins are 
extracted from the tissue and co-crystallize with the matrix. Protonated protein ions are formed by 
irradiating the matrix with a pulsed laser and are separated by mass to charge in a time-of-flight 
(TOF) mass analyzer. Protein species in the mass range of 2,000-70,000 Da are usually detected 
in the mass spectra, although protein signals with molecular weights well above 200 kDa have 
been observed [34]. Matrix solution can be deposited at different regions on the tissue section 
depending on the histology to produce distinct protein profiles from the specific regions of 
interest. Figure 1 shows an example of a frozen tissue section with matrix spots on a MALDI 
plate. The mass spectra illustrate the different protein profiles observed from a normal mouse 
breast and mouse breast tumor (Figure 1). Generally, the matrix spot and MALDI laser diameter 
determine the spatial resolution of the tissue protein profile. The spot size of commercially 
available instruments is typically focused to 60~150 micrometers in diameter. The conventional 
matrix spot delivered using a commercially available pipette is generally greater than 500
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Figure 1: Direct protein profiling from mouse breast tissue by MALDI MS. The picture 
on the left shows a tissue section with matrix solution spots. The mass spectrum on the 
top shows the protein profiles from a normal mouse breast tissue (A) and the spectrum at 
the bottom shows the protein profiles from a mouse breast tumor section (B).  
MALDI 
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2000 5000 8000 11000 14000 17000m/z
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micrometers in diameter. This spatial resolution limits the analysis of minute tissue structure 
making single cell analysis hard to achieve.  
 Although various proteomics approaches have been implemented in protein biomarker 
discovery, the sensitivity and specificity of the biomarker need to be improved. The technologies 
described above mainly detect the most abundant proteins from the sample. The less abundant or 
membrane proteins, which are not routinely detected using the current proteomic technologies, 
could be very important for understanding the mechanisms underlying the disease. Improving the 
specificity of the protein biomarker is necessary for various clinical applications. Obtaining 
protein biomarkers which are specific for a disease or different stages of a disease would greatly 
benefit the diagnosis and prognosis for patient care.   
 
Laser Capture Microdissection 
 
 
The Necessity of Tissue Microdissection  
 The heterogeneous nature of tissue presents a great challenge for genomic and proteomic 
research. When DNA, mRNA, or proteins are analyzed from a bulk of tissue, it is hard to assign 
the molecular markers of interest to any specific cell type. Identification of disease markers 
associated with the diseased cells is hindered by the complexity of tissues. The target cells, for 
example, breast tumor cells, often infiltrate irregularly into tissue and neoplastic cell are 
surrounded by large amounts of stroma, lymphocytes, blood vessels, etc, as shown in figure 2. 
Without sampling a homogenous tumor cell population, even significant differences resulting 
from the comparison of control and diseased cells could be caused by the inherent differences 
between different types of cells. For example, epithelial cells and stroma cells have different 
protein expression profiles because of different cellular functions. Furthermore, many minute 
cellular structures require special techniques to enrich a sufficient amount of sample prior to  
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Figure 2: The heterogeneous nature of tissue. The breast tumor cells are surrounded by different 
types of cells in a tissue section. The scale bar is 100 micrometer.   
Tumor Cells
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Vessel
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analysis. Rat kidney glomeruli, for example, are vital structures that filter blood in the kidney. 
They are less than one hundred micrometers in diameter and are scattered throughout the kidney 
cortex. A special technique capable of harvesting these cells is essential to assess their molecular 
changes in different disease states.    
 
Different Laser Microdissection Techniques 
 The need for obtaining a pure cell population for DNA, RNA and protein analysis in a 
heterogeneous tissue has driven the development of various cellular microdissection techniques. 
Although manual microdissection is possible [35], the reproducibility and high throughput are 
limited. Negative ablation of surrounding tissue of target cells has been used [36, 37], but a 
significant amount of valuable tissues are destroyed and the process is slow and tedious. More 
recently, two laser-assisted microdissection techniques have been developed for both paraffin and 
frozen tissue sections. One approach is called PALM, an acronym for Positioning and Ablation 
with Laser Microbeams, developed by PALM Microlaser Technology AG (Bernried, Germany) 
in 2000. In the PALM technique, tissue sections are first dehydrated through a series of alcohol 
and xylene washes. The procurement of target cells requires two steps: laser ablation and laser 
pressure catapulting. First, a highly focused beam laser (~ 3 micrometers in diameter) precisely 
ablates the outline of the selected cells. Thus, the cells within the circles are detached from the 
rest of the tissue, which yields a clear cut gap between selected and non-selected areas (Figure 
3A). Second, using the laser pressure catapulting technique, the isolated cells are ejected from the 
tissue section into a microtube cap placed above the tissue (Figure 3B). The cap is usually filled 
with fluid, such as culture medium, to catch the ejected cells. Since this liquid medium has to be 
held in the cap upside down, the medium is required to have a high surface tension. After the cells 
are collected, the solution in the cap is centrifuged down into a microtube and mRNA or proteins 
are extracted out of the cells for downstream analysis. Although the technique is effective, several  
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Figure 3: The process of P.A.L.M. laser microdissection process. A) The  laser beam precisely 
cuts an outline for the selected area on the tissue, which yields a clear cut gap between selected 
and non-selected areas. B) After microdissection, the isolated specimens are ejected from the 
tissue section and catapulted directly into the cap of a common microfuge tube.  
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Laser
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Tissue
Microdissected 
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disadvantages limit its wide application. The necessity and special requirements for the extraction 
medium dilutes the protein contents and hinders some downstream analysis techniques, such as 
the direct protein profiling using MALDI MS. The complex operational procedure and extensive 
instrumental maintenance have also contributed to its lack of popularity. Only limited 
applications have been reported using this technology, with most of these focused on measuring 
DNA or RNA levels [38, 39].  
 
Laser Capture Microdissection Mechanisms and Applications 
 The second laser assisted microdissection technique was first described in 1996 by 
Michael Emmert-Buck et al, in which a laser was used to capture the specific cells of interest 
onto a thermoplastic film [40]. Named laser capture microdissection (LCM), this technique was 
commercialized by Arcturus Bioscience Inc. (Mountain View, CA) and has become a widely 
used laser microdissection technique. 
 The principle of LCM is illustrated below. The tissue section is mounted on a regular 
histology glass slide and dehydrated with a series of alcohol and xylene washes. The glass slide is 
placed on a microscope stage with an inverted lens. As shown in figure 4, a transparent cap with 
thermoplastic film is placed on the top of the tissue section. A low power infrared laser beam is 
directed at the cells from above. This special film at the bottom of the cap is made of 
thermoplastic polymer mixed with proprietary metal. The histology of the tissue can be visualized 
under the microscope, and the specific cells of interest are positioned under the laser using a 
handle. When the operator activates the laser, the thermoplastic film is transiently melted above 
the target cells. The long polymer chains from the film infiltrate into the tissue and tightly bind 
with the selected cells underneath. The adhesion force between the film and cells separates the 
target cells from the surrounding tissue when the cap is lifted. The selected cells are embedded in  
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Figure 4: The laser capture microdissection process. (Courtesy of www.arctur.com) 
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the film which can then be placed into a buffer for extraction of either DNA, RNA or proteins for 
subsequent analysis.  
 LCM has been readily utilized for collecting pure cell populations for gene microarray 
analysis. Real-time PCR technology can amplify the mRNA from a very small amount of sample 
prior to analysis. The coupling of real-time PCR and LCM have been applied to many areas in the 
biomedical science, such as cancer research [41-43], neurological disease [44], proteinuric 
disease [45], HIV disease [46], and studies of hormonal receptors [47]. However, unlike mRNA, 
proteins cannot be amplified after the sample collection, thus the limited number of cells obtained 
using LCM technique cannot be easily applied to traditional proteomic analysis. For example, 
50,000 to 100,000 cells are required for one 2D-PAGE experiment [48, 49]. Obtaining this large 
amount of cells manually is very labor-intensive, and cannot be done routinely and limits any 
high throughput analysis. Therefore, combining LCM with the direct tissue analysis using 
MALDI MS offers an attractive approach for obtaining protein profiles from a small population 
of highly selected cells.  
 
Significance of Method Development 
 Since both LCM and direct tissue protein profiling using MALDI MS offer unique 
strengths, combining these two techniques would be expected to have a significant impact on 
proteomic research. After the specific cells of interest are microdissected on the LCM film, 
instead of immersing the sample in protein extraction buffer, the LCM film with the 
microdissected cells can be mounted on a MALDI target plate. The protein contents from the 
captured cells can be analyzed directly using MALDI MS after applying matrix solution. 
Although this concept was proposed previously by Palmer-Toy et al [50], only a few protein 
signals with low resolution were detected from the cells obtained by LCM. The application of this 
technology is difficult without dramatically improving the sensitivity. Several protocols of the 
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LCM methodology need to be optimized and various aspects of the method need to be evaluated. 
With abundant protein signals detected, the mass spectra obtained will better reflect the protein 
expression profiles of the microdissected cells. Combining downstream statistical analysis and 
protein identification, this approach will offer a unique and powerful technology for protein 
marker discovery.  
 This seemingly straight forward method of combining LCM and MALDI MS has 
multiple advantages compared to the current proteomic approaches, such as 2-D gel 
electrophoresis. First, the protein expression profiles are acquired only from cells of interest. The 
pure cell population obtained using LCM minimizes the risk of mixing inherent differences 
existing among different types of cells into the final results; therefore, the protein profiles 
comparison is much more relevant and meaningful because cells from the same origin are 
compared. Second, this method is very sensitive because of the high sensitivity of MALDI-TOF 
MS. Protein profiles can be obtained directly from only a few cells, which dramatically reduces 
the amount of time and effort required in the microdissection step. Studies which have only little 
amounts of materials are possible with this technique. Minute tissue structures can be analyzed 
directly without sample enrichment. Third, the time required for obtaining protein profiles is very 
short. After the cells are microdissected, the protein profiles can be generated within 20 minutes. 
Compared to the days 2-D PAGE takes, this high throughput method can be applied to a large 
cohort of samples to achieve statistically significant results. For example, human tumor biopsies 
are very heterogeneous due to environmental and genetic variabilities. Analyzing a large number 
of samples is essential to achieve statistically significant results. Fourth, relatively small proteins 
and peptides which cannot be easily analyzed by 2-D PAGE are accurately measured using this 
technique. This offers a great complementary technique for the 2-D PAGE and multidimensional 
LC-MS/MS approaches.  
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Research Objectives 
 The technical protocols involved in combining LCM and MALDI MS for protein 
profiling of cells must be optimized and evaluated. It is expected that the application of this 
methodology to various biological systems will aid the discovery of relevant disease-specific 
protein markers. Furthermore, this approach can be applied to the discovery of new neoplastic 
tumor markers, new tumor classification, elucidation of pathomechanisms, and prediction of 
disease progression. Therefore, the following specific objectives are formed for this research: 
 
Objective 1: Develop a reliable and reproducible method for the direct acquisition of protein 
expression profiles from the cells obtained by LCM using MALDI MS. 
 
Objective 2: Apply the method developed in Objective 1 to various biological systems for the 
purpose of: 
1) Identifying protein markers differentially expressed in normal and neoplastic mouse 
colon. 
2) Obtaining proteomic patterns to begin classifying glomerulosclerosis at the protein level 
and to advance the understanding of glomerulosclerosis mechanisms.  
3) Classifying human breast tumor from normal breast tissue and begin to distinguish in situ 
from invasive cancer at the protein level. 
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CHAPTER II 
 
METHODOLOGY DEVELOPMENT 
 
The combination of LCM and MALDI MS is an ideal discovery tool to obtain protein 
profiles from a pure cell population sampled in a heterogeneous tissue [50, 51]. Although holding 
great promise in the proteomic field for various biological systems, there are several technical 
challenges to overcome for this technology to become a reliable and sensitive technique. First, a 
system needs to be developed to accurately deliver matrix solution to the small number of cells 
captured on the LCM film. LCM has the potential of capturing a single cell, which usually is 
approximately 10 micrometers in diameter. Regular pipettes cannot deliver the small amount of 
matrix solution needed to just cover the captured cells. Excess matrix dilutes the proteins and 
decreases the MALDI MS sensitivity. Second, conventional used histological staining, such as 
haematoxylin and eosin, may suppress the protein ionization process affecting the mass spectra 
sensitivity, mass accuracy and reproducibility. Histological staining that is compatible with LCM 
and MALDI MS needs to be explored. Third, the ethanol and xylene dehydration process required 
by LCM can potentially wash away some of the highly soluble proteins from the tissue. Therefore, 
the dehydration effects on protein profiles need to be evaluated. Fourth, the effects of the LCM 
polymer film on MALDI MS analysis need to be assessed.  
The procedures for sample preparation for LCM and MALDI MS analysis must be 
optimized to achieve highly sensitive and reproducible results required for tissue protein profiling. 
For this reason, the practical aspects of tissue section preparation, the LCM process, matrix 
solution deposition, and MALDI mass spectra acquisition are described in this chapter. The 
effects of different histological staining, alcohol dehydration and the LCM thermoplastic film on 
MALDI MS analyses are also evaluated and discussed.   
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Tissue Preparation for Laser Capture Microdissection 
 
Tissue Sectioning and Dehydration 
Proper tissue sectioning and dehydration are important prerequisites to achieve optimal 
results using LCM. We have found previously that surgically procured tissue samples should be 
snap-frozen in liquid nitrogen and stored in a liquid nitrogen tank or a –80°C freezer prior to use 
[34]. Five micrometer thick sections are generally cut using a cryostat and mounted on regular 
histological glass slides without the contamination of embedding media, such as OCT. Sections 
of greater thickness can also be cut for LCM in an instance where the tissue sample is too small 
or the structure is too loose to be cut at five micrometer thickness. Formalin fixed tissue samples 
are not suitable for downstream MALDI MS analysis due to the protein cross linking; therefore, 
only frozen tissue sections are used in this study. 
 Complete dehydration of the tissue sections is an important procedure because this 
ensures an effective transfer of cells to the LCM cap. The presence of water within the tissue 
section inhibits good capture of the cells. The dehydration should be started immediately after the 
tissue is mounted on the glass slide. Delaying dehydration will cause the tissue section to adhere 
to the glass slide irreversibly, and the cells cannot be microdissected. Briefly, the sections were 
processed as follows: 70% ethanol for 30 second, 95 % ethanol for 1 minute, 100% ethanol for 1 
minute (times 2), xylene for 2.5 minutes (times 2), and  air dry for 5 minutes.   
 
The Laser Capture Microdissection Process 
Prior to laser capture microdissection, the Arcturus Prep-strips (Mountain View, CA) are 
applied to the dehydrated tissue sections to remove any attached loose particles, such as tissue 
debris. The glass slide is placed on the LCM microscope stage and one CapSure cap is gently 
placed on top of the tissue section. The laser from the LCM instrument is focused and the laser 
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power is optimized. A round shaped ring with a black circle is observed when the laser is fired on 
the LCM film as an indication for a well focused laser beam. Three different laser spot sizes can 
be chosen depending on the microdissection resolution requirement, as shown in Figure 5. Cells 
cannot be captured if the laser is not well focused or the laser power is not high enough. The laser 
duration time is adjusted according to the spot size required. Table 1 lists the reference range for 
the laser power and duration time for different laser spot sizes. When the laser is activated the 
film softens, flows out and adheres to the target cells. The film resolidifies with the adhering cells 
attached to it. When the cap is lifted, the cells are microdissected from the surrounding tissue. 
After the microdissection, the cap is removed from the microscope stage and enclosed in 
an eppendorf tube to avoid contamination. If MALDI MS analysis cannot be performed on the 
same day, the LCM caps are stored at -80°C freezer. Prior to MALDI analysis, the LCM caps are 
warmed to room temperature in a vacuum desiccator to avoid moisture condensation.  
 
Mounting the LCM Film on MALDI Plate 
 After the LCM cap is removed from the eppendorf tube, the film at the bottom of the cap 
is gently peeled off using a pair of fine tweezers. A piece of double-sided conductive tape (Digi-
Key, Thief River Falls, MN) is mounted on a polished, gold-coated MALDI target plate. The 
LCM film is mounted flat on the conductive tape with the captured cells facing upward (Figure 
6A). An Arcturus prep-strip is applied to ensure no air bubbles exist under the film. Multiple 
LCM films may be placed on one MALDI plate.  
  
Matrix Solution Deposition 
Due to the small number of cells captured on LCM film, conventional pipettes cannot 
deliver matrix solution droplets small enough to cover only the cells. Excess matrix solution 
deposited with a conventional pipette dilutes the cellular contents and the resulting large matrix 
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crystal makes it difficult to locate the cells. The MALDI mass spectral quality is therefore 
degraded and the sensitivity of this technique suffers. To improve the sensitivity, micro-spotting 
only appropriate amounts of matrix solution needed to cover the captured cells is a key step.  
Though multiple techniques are available for small droplet deposition, a special approach 
has to be taken for this research because the sinapinic acid matrix solution crystallizes and clogs 
the line tips very quickly. Utilization of a special manually controlled pulled glass capillary is a 
good approach for several reasons: 1) the opening tip of the capillary can be cut with a 10 
micrometer diameter and used to deliver sub-nanoliter volumes of solution to cover the captured 
cells. 2) Manually controlling the capillary enables the deposition in a fast fashion, thereby 
avoiding the matrix clogging problem. 3) The glass capillary is low cost and disposable. 
Changing a new capillary for each sample is practical and avoids possible cross contamination. A 
new capillary can be used if it gets clogged.  4) The surface tension of the glass capillary 
automatically draws in matrix solution. The matrix solution can be deposited onto target cells by 
touching the capillary tip to the captured cells.   
The matrix solution is deposited onto the captured cells under microscope visualization. 
The matrix solution, typically consisting of 20 mg/ml sinapinic acid in 6/4/0.03 v/v/v 
acetonitrile/water/TFA, is drawn into the capillary by dipping the tip into the matrix solution for 
several seconds. The MALDI plate with the LCM film is placed on the microscope stage. The 
captured cells can be clearly visualized under 4X object lens with proper light from above. The 
capillary tip loaded with matrix solution is gently touched to the surface of the cells (Figure 6B) 
and the matrix solution is deposited onto the cells. The matrix solution forms crystals several 
seconds after deposition on the cells (Figure 6C). The volume of matrix solution deposited ranges 
from approximately 100 pl to 10 nl depending on the number of microdissected cells.    
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Figure 5: The expected shape for a well focused laser spot on a LCM film. Three different laser 
spot sizes were presented. The scale bar is 30 micrometer.  
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Table 1: The reference ranges of laser power and duration for focusing LCM laser at different 
spot sizes. These specifications are for the CapSures caps from Arcturus Co. (Courtesy form 
Arcturus Co.) 
 
 
 
5.0-6.0 ms25-35 mWLarge (30 µm)
1.5-2.0 ms30-40 mWMedium (15 µm)
550-650 µs40-50 mWSmall (7.5 µm)
LASER DURATIONLASER POWERLASER SPOT SIZE
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Analyzing the Laser Capture Microdissected Cells by MALDI MS 
Sensitivity  
 To evaluate the sensitivity of this technology, various numbers of cells were 
microdissected by LCM and analyzed using MALDI MS. For comparison, 5, 20, 40, 80, 160, and 
320 cells were microdissected from serial mouse cecal tumor tissue sections. Matrix solution was 
micro-deposited onto the captured cells. For MALDI MS analysis, the laser intensity remained 
consistent throughout the experiment and one hundred laser shots were acquired per mass 
spectrum. The mass spectra obtained from these cells were shown in figure 7. Protein signals can 
be detected with as few as 5 cells. As the number of microdissected cells increases, the signal to 
noise ratio and number of peaks detected increase gradually from 20 cells to 160 cells and level 
off between 160 and 320 cells. Therefore, capturing at least of two hundred cells was enough for 
obtaining high quality mass spectra, while also dramatically reduces the microdissection time and 
allowing for analysis of small amount of target cells.  
 
Reproducibility 
 The reproducibility of this technique is evaluated with protein profiles obtained from two 
independently prepared tissue sections from a mouse cecal tumor sample. The tumor sample is 
very homogenous according to the histology and the same numbers of cells were captured by 
LCM and analyzed using MALDI MS. Mass spectra were acquired from five different regions 
and averaged to represent the protein expression profile from one tissue section. Similar 
experiments were performed two weeks later on the same frozen tumor. The MALDI spectra 
were baseline corrected and the intensities were normalized to the total ion current. The 
intensities of the 164 most intense peaks found in the two spectra were compared, as shown in 
figure 8. The results show that 151 of these 164 peaks are within 1.5-fold changes for the two 
 
 
 
22
 
 
 
 
 
 
    
 
 
 
Figure 6: LCM films adhered to a MALDI target plate with double sided tape (A).  (B) shows the 
captured cells on the LCM film prior to matrix deposition, and (C) shows the matrix solution 
crystallize on top of the captured cells.  
Gold-coated MALDI plate
Double-sided Tape
LCM FilmCaptured Cells
30µm
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Figure 7: The sensitivity assessment for combining LCM and MALDI MS. Protein signals were 
observed from 5 cells and the signal-to-noise ratio were improved slightly as the number of cells 
captured increases.  
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different analyses, and no peaks were found having more than 2 fold changes. The R squared 
value is 0.968 for the linear regression fit. This result demonstrates that highly reproducible mass 
spectra are obtained using this technology.  
 
Dehydration Effect 
The dehydration procedure required by LCM contains several graded alcohol wash steps 
which may remove some highly soluble proteins from the tissue sections. To evaluate the effect 
of dehydration on obtaining reproducible protein profiles, three mouse liver sections were treated 
as follows: a) a control tissue section with no treatment; b) a tissue section was emerged in 70% 
ethanol for 1min; c) a tissue section was emerged in water for 3 minutes. Matrix solution was 
then deposited on the three tissue sections at similar regions and MALDI mass spectra were 
generated from these matrix spots. No significant differences in the three spectra were found 
(Figure 9), which shows that the tissue dehydration process required in preparation for LCM does 
not cause significant protein loss from the tissues. Though a few peptides were found by 
subsequent MALDI analysis of the washed ethanol solution, these same peptides were also 
detected from the washed tissue sections with similar intensities compared to control, suggesting 
sufficient proteins remained in the tissue after the wash procedure. Some physiological salts from 
the tissue, which interfere with the MALDI ionization process, are also washed away in the 
dehydration procedure. Thus washing steps can help improve the MS quality.  
 
Comparison with Direct Tissue Protein Technique 
Other sample preparation steps required by LCM, such as cell capture and transfer via the 
thermoplastic film, may influence the protein profiles when comparing them with the results from 
direct tissue analysis. To evaluate the potential differences, a mouse cecal tumor, which was 
homogenous according to the histology, was cut at 5 µm sections. For the LCM approach,
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Figure 8: Reproducibility analyses of protein expression profiling with LCM combined with 
MALDI MS. Comparison of two spectra obtained from the same sample but different 
independently prepared sections at different days are presented.  
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Figure 9. The tissue dehydration process required in preparation for LCM does not result in 
significant protein loss from the tissues.  MALDI MS spectra of A) Untreated mouse liver, B) 
mouse liver after exposure to 70% ethanol for 1 minute, and C) mouse liver after exposure to 
water for 3 minutes.   
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approximately 2000 tumor cells were captured from the tissue sections. Seven individual mass 
spectra were obtained and averaged as one (Figure 10A). For the direct tissue analysis, six 150 nl 
droplets of matrix solution were deposited on the tissue sections. Six mass spectra were obtained 
from the tissue sections and averaged as one (Figure 10B). The experiment was repeated three 
times on three different samples and similar results were obtained. For the comparisons, the 
overall protein profile qualities acquired using both approaches were similar in the number of 
signals detected and peak mass range. Though the mass spectra obtained using the direct tissue 
analysis approach had better signal-to-noise ratio and resolution for some peaks. Some peak 
intensity differences were also observed in the two mass spectra, such as the peaks detected at 
4898, 9738, 11055 and 15711 m/z. Therefore, using one consistent technique is necessary for 
tissue protein profiling and comparison.  
 
Staining Effect 
 Histological staining facilitates the recognition of various cell types in tissue and is 
commonly used in pathology. Haematoxylin and eosin (H&E) is a widely used staining method 
and its effect on obtaining protein profile using MALDI MS was evaluated with mouse liver 
sections. Both the control tissue and H&E stained tissue sections went through the same 
dehydration preparation steps, except the control section skipped the H&E staining. Figure 11 
shows the mass spectra obtained from H&E stained and controlled tissue sections. The spectrum 
obtained from the unstained cells (Figure 11 B) clearly shows more signals and better resolution 
when compared to those of stained cells (Figure 11 A). Therefore, H&E tissue staining prior to 
LCM severely interfered with the MALDI mass spectrum quality.  
 Since histological staining is necessary for recognition of some special cell types, 
development of a staining protocol which is compatible with MALDI MS analysis is important
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Figure 10: The comparison of MALDI MS from (A) LCM cells and (B) direct tissue sections. 
The overall mass spectra qualities were similar when obtained using both of the approaches, 
though peak intensity differences were observed for some peaks as labeled.  
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Figure 11. The histological staining of tissue prior to LCM reduces spectrum quality. (A) MALDI 
MS spectrum obtained from haematoxylin and eosin (H&E) stained LCM captured mouse liver 
cells. (B) MALDI MS spectrum obtained from unstained LCM captured mouse liver cells.   
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for accurately selecting cells of interest using LCM. The compatibilities of cresyl violet and 
methylene blue with LCM and MALDI MS analysis were further evaluated [52]. Consecutive 
mouse liver sections were cut and stained with cresyl violet and methylene blue. Approximately 
400 hepatic cells were microdissected by LCM and analyzed using MALDI MS. For both Cresyl  
violet and methylene blue, the dehydration steps did not destain the sections. Figure 12 shows the 
protein profiles obtained from unstained, methylene blue and cresyl violet stained microdissected 
cells in the m/z range from 3000 to 30000. The overall spectral quality, resolution and signal 
intensity, were evaluated and found to be in good agreement with the signals recovered from 
unstained control section. The spectra obtained from methylene blue-stained cells were found 
remarkably similar to those obtained from control cells over the entire studied m/z range. The 
profiles acquired from cresyl violet-stained cells showed some signal intensity differences from 
the control profiles. For example, the signals at m/z 9911, 14287, and 29281, which were detected 
with strong intensity in the control cells, were detected with lower intensities after cresyl violet 
staining. As a general trend, stronger intensity signals were obtained after cresyl violet staining in 
the m/z range below 12000. However, signals in the m/z range above to 18000 were better 
detected from the control or methylene blue stained cells.  
 
LCM Film Effect 
The thermoplastic polymer film used in LCM is non-conductive and may accumulate 
excess charges on the surface during the MALDI process. These accumulated charges may distort 
the local electrical potential and interfere with the mass accuracy and peak resolution. Therefore, 
internal calibration is applied for each MALDI MS analysis to compensate for the surface 
charging effects. To evaluate the mass accuracy with internal calibration, standard proteins, 
insulin and apomyoglobin, were spotted on the LCM film and measured using MALDI MS. With 
the internal calibration of insulin and apomyoglobin peaks, the mass accuracy for the doubly 
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Figure 12 (a-c) LCM of Cresyl Violet-stained mouse hepatic cells. MALDI-MS protein profiles 
obtained from microdissected mouse hepatic cells. Ct, control; MB, stained with Methylene Blue; 
and CV, stained with Cresyl Violet.  
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charged apomyoglobin peak was evaluated. Fourteen consecutive 100 laser shot mass spectra 
were acquired, and an average mass accuracy of 60 ppm with 40 ppm standard deviation was 
obtained. This mass accuracy is acceptable for linear MALDI MS analysis. Therefore the mass 
accuracy did not suffer using the LCM procured cells with internal calibration.  
 Another possible effect caused by the polymer film is that polymeric peaks may be 
observed in the lower mass range if the MALDI laser intensity dramatically exceeds the normally 
required level. Polymer peaks can be detected from the LCM film and are usually under 4000 Da 
(figure 13). Abundant protein signals across a wide mass range can be detected without 
generating these polymer peaks with proper adjusted laser intensity (figure 7, 8 and 12). 
Therefore the MALDI laser intensity should be controlled properly to avoid possible polymer 
peaks.  
 
Summary and Conclusions 
 With the optimized sample preparation procedure, LCM combined with MALDI MS is a 
sensitive, accurate, fast and reliable method to acquire protein profiles from a specific cell 
population sampled in a heterogeneous tissue. In this chapter, the sample preparation protocol for 
providing high quality mass spectra is described and various aspects of this technology are 
evaluated. The matrix solution microspotting technique and development of MS compatible 
histological staining significantly improved the reliability and sensitivity of this technology. The 
dehydration process and the LCM film were evaluated and did not show significant interference 
with the protein profile quality.  
LCM combined with MALDI MS has great applications in a wide range of biological 
systems. Its unique ability to quickly and accurately generate protein profiles from small numbers 
of pure cells from a heterogeneous tissue has extraordinary utility in finding disease marker, 
elucidating pathomechanisms, and classifying tissue subtypes at the protein levels. It also has the     
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Figure 13:  The polymer peaks are found on from LCM film when MALDI laser intensity is too 
high. The polymer peaks presents under 4000 Da and can be eliminated by lowering the MALDI 
laser intensity.  
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potential to play an important role in clinical applications for disease diagnosis and prognosis. 
 
Materials and Methods 
 The sinapinic acid, cresyl violet, methylene blue and the standard proteins were 
purchased from Sigma Chemical (St. Louis, MO). Trifluoroacetic acid (TFA) was from Burdick 
and Jackson (Muskegon, MI). HPLC grade acetonitrile was from EM Science (Merck, Darmstadt, 
Germany). The ethanol was from AAPER alcohol, absolute 200 proof (Shelbyville, KY) and 
xylene is from Pharmco (Brookfield, CT). The frozen mouse cecal tumor samples are a courtesy 
from Dr. Nipun Merchant.  
Tissue sections were cut on a CM1800 cryostat from Leica Microsystems (Wetzlar, 
Germany). Laser capture microdissection was performed using the Arcturus PixCell II LCM 
system and the CapSure caps were from Arcturus Co. (Mountain View, CA). For LCM, the laser 
duration time was 800 microseconds and the laser power was 75mW. The double-sided tape is 
from Digi-Key Co (Thief River Falls, MN). 
 The 7” length Drummond glass capillary used for oocyte injection from Drummond 
Scientific Co. (Broomall, PA, USA) is utilized for making the matrix solution deposition capillary. 
The capillary is pulled in a P-87 Laser Based Micropipette Puller from Sutter Instrument Co 
(Novato, CA, USA). The pulling program is set as follows: First cycle: Heat 780, Pull 50, Vel 26, 
Time 35; Second cycle: Heat 780, Pull 50, Vel 10, Time 15. After the glass capillary is pulled, the 
opening of the tip is cut using a razor blade, leaving the opening of the capillary approximately 10 
micrometer in diameter.  
Methylene blue is prepared in 0.15% in 70% ethanol. The solution is stirred overnight 
and filtered before use. Cresyl violet was prepared in 0.5% deionized water and stirred overnight 
on low heat. The cresyl violet solution was filtered and 2 drops of glacial acetic acid was added to 
a 100-mL solution. The tissues were stained 10 seconds in methylene blue and 30 seconds in 
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cresyl violet solution, and then followed with the graded ethanol and xylene dehydration process. 
Hematoxylin and eosin were from Richard-Allan Scientific (Kalamazoo, MI). The hematoxylin 
and eosin stains procedure was 1 min in 70% ethanol, 30 s each in hematoxylin followed by eosin, 
20 s in water, followed by previously described ethanol and xylene wash steps.  
MALDI-MS analysis was performed using a Voyager DE-STR MALDI-TOF mass 
spectrometer from Applied Biosystems (Framingham, MA) with a 337 nm nitrogen laser. The 
mass spectra are acquired in the linear mode to accommodate the wide mass range. The optimized 
delayed extraction condition for this research is set as follows: the accelerating voltage is 25,000 
V, the grid voltage is 91%, and the delay time is 220 nano-seconds. To obtain the best sensitivity, 
the guide wire is set at 0.055%.  
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APPLICATIONS TO BIOLOGICAL SYSTEMS 
 
Introduction  
 The optimized protocol developed for direct protein profiling from laser microdissected 
cells using MALDI MS was described in chapter II. Many significant biological questions which 
cannot be easily studied with other proteomic technologies can be addressed using this 
technology. This technique can be virtually applied to any type of frozen tissue. Several different 
applications are discussed in this chapter, including finding early protein markers in normal and 
neoplastic mouse colon, classifying human breast tumors subsets, and predicting rat kidney 
glomerulosclerosis. The general strategy for these studies is shown in Table 2. Briefly, the 
specific populations of cells were first obtained from the frozen tissue sections using laser capture 
microdissection. Second, the protein expression profiles were acquired using MALDI mass 
spectrometry. Third, after proper data processing, such as mass spectra calibration, baseline 
correction and peak binning, multi-functional statistical analyses were performed and statistically 
significant protein markers were selected. Proteomic patterns unique to each tissue group were 
obtained. The different tissue groups were clustered using these proteomic patterns. Finally, the 
most significant protein markers were separated from the tissue lysate and identified through 
amino acid sequence analyses using tandem mass spectrometry. Further functional analyses of 
these differentially expressed protein markers will not only advance our understanding of the 
pathomechanisms and aid in elucidating potential drug targets, but the disease specific proteomic 
patterns also have the potential to serve as diagnostic and prognostic tools for better patient care 
and treatment.  
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Table 2. Overview of the general strategy for elucidating differentially expressed protein markers 
using LCM combined with MALDI MS technology.  
 
   
 
   
 
 
 
Selecting Cells of Interest Using LCM
Protein Profiling Using MALDI Mass Spectrometry 
Processing Mass Spectra for Data Analysis
Elucidating Significant Protein Patterns using 
WFCCM and Eisen's Statistical Methods
Identifying Significant Protein Markers with 
Sequence Analysis by Tandem Mass Spectrometry
Confirm the Differentially Expressed Protein 
Markers with Immunohistochemistry
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CHAPTER III 
 
PROTEIN PROFILING OF NORMAL AND NEOPLASTIC MOUSE INTESTINE 
 
Introduction 
 Colorectal cancer (CRC) is the fourth most common cancer and the second most common 
cause of cancer deaths in the US, with estimates of more than 146,940 new cases and 56,730 
deaths for the year 2004 [53]. Although significant improvements have been made in the 
treatment of CRC with surgery, chemotherapy and the combination of radiotherapy-
chemotherapy, patients with advanced CRC still have a poor prognosis. Early diagnosis and 
improved understanding of the biological behavior of each tumor is vital for the success of 
treatment. Identification of early colorectal tumor markers at the protein levels is expected to 
make significant improvements for better understanding of CRC mechanisms, as well as assisting 
clinical diagnosis, prognosis and treatment for CRC patients.     
 Colorectal neoplasia initially arises from colonic crypts (Figure 14A). A normal mouse 
crypt is only 30 micrometers in width and 250 micrometers in length (Figure 14B).  Crypt cells 
continue to rapidly proliferate throughout life. A small number of stem cells situated near the 
bottom of the crypts give rise to various daughter cells, such as absorptive cells, endocrine cells, 
goblet cells, and tuft cells [54-56] (Figure 15A). These daughter cells migrate from the crypt base 
to the luminal surface and are shed into the lumen of the colon. Steady supplies of cells are 
generated in the bottom crypt compartment to replace the shed cells (Figure 15B). In mouse, 
daughter cells migrate from the bottom crypt to the top in approximately 7 days with up to 60% 
of the crypt cells dividing twice daily [57]. Hence the differentiated cells are found mainly toward 
the top of the colonic crypts. Currently, little is known about the factors that control the stem cells 
proliferation, differentiation and their roles during malignant process. 
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Figure 14: The histology and size of mouse colonic crypts and polyps. A). The histology of a 
mouse colon with normal crypts. The top compartments of crypts open to the lumen of the gut 
and stem cells reside at the crypt base. B) An isolated crypt on a MALDI plate with a penny for 
size reference. The average length for mouse colonic crypts is 250 µm. The top and bottom 
compartments were separated with dotted lines. C). The histology of adenomas from an ApcMin/+ 
mouse polyp.  
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Figure 15: The biology and structure of colonic crypt. A). The stem cells give rise to various 
daughter cells. Little is known about the factors that control the stem cell proliferation and 
differentiation. B), The cells situated at the crypt base constantly proliferate and migrate up to the 
top crypts and shed away into the lumen.  
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The proliferative, progenitor compartment is speculated to have a different protein expression 
profile compared to the post-replicative, differentiated compartment in the upper portion of the 
crypt. Stem cells at the crypt base cannot be identified morphologically or distinguished using 
molecular markers from their surrounding epithelial cells. Identifying the unique protein patterns 
for the top and bottom crypt compartments may advance our understanding for the mechanisms 
that control stem cells renewal, proliferation and the roles they play in colorectal neoplasia 
development. Therefore, the proteomic patterns from the normal top and bottom of crypt 
compartments serve as important references for comparison with colonic neoplasia.     
  During colorectal cancer development, adenomas or polyps are the early benign neoplasia 
originated from crypts. An excellent animal model for obtaining adenomas in intestines is the 
ApcMin+/- mouse model. The multiple intestinal neoplasia (Min) mouse model is a germline mutant 
mouse model of gastrointestinal malignancy [58] with a mutation in the adenomatous polyposis 
coli (APC) gene. The APC gene codes for a 312 kDa cytoplasmic protein with 2843 amino acids. 
Loss of APC gene function is often the first genetic event in the cascade of genetic events that 
lead to malignant transformation in colon. Mutations in the APC tumor-suppressor gene have 
been detected in ~80% of all human CRC [59]. Alterations in the APC gene prevent proteasome-
mediated degradation of β-catenin, a key player of the Wnt signaling pathway. As a consequence, 
β-catenin is stabilized in the cytosol and translocated to the nucleus, where it participates in the 
transcription of a number of Wnt responsive genes and initiate colonic neoplasia transformation 
[60]. Intercellular adherens junctions and cell contacts regulation were also increased as result of 
elevated level of E-cadherin from APC gene mutation [61]. These changes in cellular contacts 
may explain how APC-mutated cells manage to remain within the crypts. In addition, APC is an 
important regulator of the microtubule cytoskeleton and plays a role in cell migration [62]. 
ApcMin/+ mice develop on average of 35 adenomas in the small intestine and colon [63]. Similarly, 
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familial adenomatous polyposis (FAP) human CRC patients have mutations in the APC gene and 
develop hundreds of adenomatous polyps in colon and rectum.  
 The limited size of mouse colon crypt presents a challenge for conventional proteomic 
techniques such as 2-D gel electrophoresis. Different regions of each crypt only contain around 
10 cells in 10 µm thick tissue sections. Thus, the analysis of different crypt compartments 
requires a special technique to harvest these very limited cell populations. The adenomas from 
ApcMin+/- polyps are heterogeneous, composed of epithelium, stroma and various other cells 
(figure 16). The tumor cells should be specifically selected to compare with epithelial cells from 
normal crypts. Laser capture microdissection combined with MALDI-TOF MS offers a powerful 
technique to analyze the protein expression profiles from these limited and specific cells of 
interest. In this study, the protein profile analyses were performed using LCM and MALDI MS. 
Differentially expressed proteomic patterns were found that upon statistical analyses 
distinguished normal crypts from adenomas. Significant protein markers were identified through 
amino acid sequence analysis using tandem mass spectrometry. Immunohistochemistry was 
performed on some of the protein markers to confirm their differential expression.  
 
Specific Aim 
To identify specific proteomic patterns unique to different colonic crypt compartments 
and ApcMin+/- adenomas to aid early colorectal cancer diagnosis.   
 
Results 
Protein Profiles of Top and Bottom of Normal Crypts and Adenomas 
Normal crypts were microdissected from adult wild-type C57/BL6 mice. The LCM 
process is illustrated in Figure 17. Different crypt compartments are clearly recognized from the  
 
 
 
43
 
 
 
 
 
 
    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. The heterogeneous nature of ApcMin+/- adenoma with adjacent normal colon. 
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longitudinal cut crypts (Fig 17a). In each tissue section, the bottom third of the crypts was first 
microdissected using LCM (Fig 17b). The cells from the top of the crypt were also 
microdissected using LCM for comparative purposes (Fig 17c). Although a single LCM laser shot 
captures approximately ten crypt cells (Fig 17d), which was sufficient to generate a good quality 
mass spectrum, we chose to capture approximately 10 crypt bottoms to obtain a more broadly 
representative cell population. Capturing more than 100 cells did not significantly improve the 
quality of the mass spectra. The microdissected cells from the top and bottom of crypts are shown 
in Figure 17e and 17f, respectively. A total of 68 and 62 individual groups of cells were captured 
from 4 adult wild-type C57/BL6 mice. Similarly, epithelial cells of adenomas from ApcMin+/- mice 
polyps were obtained using LCM with minimal amount of the contamination of surrounding 
stroma cells. Approximately 100 cells were captured for each group of microdissected adenomas. 
A total of 78 individual groups of adenomatous cells were microdissected from 8 adult C57/BL6 
ApcMin+/- mice.  
 The protein expression profiles were directly acquired from the microdissected cells 
using MALDI-TOF MS. Each mass spectrum was acquired from an individual group of 
microdissected cells. The representative mass spectra for the top and bottom of the crypt and 
adenomas are shown in figure 18A-C. Different protein expressions were shown in the three 
groups. For each mass spectrum, approximately 200 significant signals were detected in the 
protein mass range 2000 to 70,000 Da, with proteins under 20,000 Da yielding the best 
resolution. After internal calibration, the spectra were baseline corrected and normalized using an 
algorithm developed in our laboratory.  
 
Proteomic Patterns Classifications among the Top and Bottom of Normal Crypts and Adenomas  
 A total of 68 and 62 individual MALDI mass spectra were obtained from the normal top 
and bottom crypts, respectively and 78 mass spectra were obtained from the adenomas. The
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Figure 17: The process of using LCM to microdissect the specific cells from the top and bottom 
of crypts. a) longitudinal crypts were chosen for microdissection; b) and c) shows the crypts after 
the bottom and top compartments were microdissected, d) To illustrate the size and positions 
where LCM laser hits, black circles were shown on the parallel cut tissue section stained with 
H&E. Approximately 10 cells were captured per laser hit. The scale bar is 30 µm; e) and f) show 
the captured cells from the bottom and top crypt compartments on the LCM films.  
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Figure 18: The different protein expression profiles for the top (A), bottom murine colonic crypts 
(B) and murine colonic adenomas (C). As marked with a *, different protein expression patterns 
were observed in the different intensities in the mass spectra.  
 
4000 7200 10400 13600 16800 20000
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
(A)
(B)
(C)
*
R
el
at
iv
e 
In
te
ns
ity
20000 26000 32000 38000 44000 50000
m/z
(A)
(B)
(C)
* *
*
*
*
*
*
*
 
 
 
47
signals across all these spectra were compared and over 1400 distinct peaks were obtained. To 
detect significant protein markers that were expressed differently among the top and bottom of 
crypts and adenomas, advanced statistical analysis was performed to analyze the enormous 
amount of data. Weighted flexible compound covariate method (WFCCM) program utilizes six 
different statistical tests to determine discriminatory markers [64]. This statistical method has 
been successfully applied to classifications of different tumor subsets in non-small cell lung 
cancer based on proteomic patterns [22]. According to the statistical criteria, the top biomarkers 
determined from the comparisons of three different groups (normal top, bottom crypts and 
adenomas) were obtained. The most significantly differentially expressed protein signals are 
shown in table 3, organized according to the classification group in which the marker was 
overexpressed. 
 Using the statistically significant biomarkers resulting from the WFCCM analyses, the 
protein profiles from the three different groups were compared and classified. The classification 
accuracy was assessed using the leave-one-out cross-validation class prediction method (Table 4). 
The protein profiles from the normal top and bottom crypts were successfully distinguished from 
each other with 97% accuracy based on the top 77 differentially expressed protein markers. This 
result clearly demonstrates the proteomic differences that were detected between the top and 
bottom crypts. For the comparisons among the adenomas and different crypt compartments, 
100% classification accuracy was achieved for both the top and bottom crypt compartments vs. 
adenomas, using the top 40 and 20 differentially expressed protein markers, respectively. 
Therefore, these different tissue populations are all successfully classified from each other based 
on the proteomic patterns.  
 An agglomerative hierarchical clustering algorithm [65] was used to further verify and 
visualize the differential protein expression patterns selected by the WFCCM analysis. For the 
normal top and bottom crypt comparison, 128 out of 130 protein profiles were correctly clustered 
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Table 3: Top differentially expressed protein markers determined by weighted flexible compound 
covariant method (WFCCM) analysis. The average m/z value is reported. Biomarkers are 
grouped according to the classification in which the marker was overexpressed.  
 
 
Adenomas / Bottom Crypt
Bottom Crypt10718.3
Bottom Crypt9977.8
Bottom Crypt8982.2
Bottom Crypt8585.8
Bottom Crypt8432.0
Bottom Crypt8418.9
Bottom Crypt6799.2
Bottom Crypt5028.9
Bottom Crypt4450.2
Bottom Crypt3950.2
Bottom Crypt3326.3
Adenomas14950.5
Adenomas14791.8
Adenomas10166.9
Adenomas4442.4
Adenomas4315.1
Adenomas4274.1
Adenomas4078.4
Adenomas4060.6
Tissuem/z
Adenomas / Top Crypt
Top Crypt21179.7
Top Crypt15995.7
Top Crypt15852.4
Top Crypt15619.4
Top Crypt14983.0
Top Crypt13471.6
Top Crypt12435.8
Top Crypt11055.8
Top Crypt10827.2
Top Crypt10718.3
Top Crypt10589.7
Top Crypt10184.6
Top Crypt9977.8
Top Crypt9452.8
Top Crypt9078.3
Top Crypt8982.2
Top Crypt8639.6
Top Crypt8626.2
Top Crypt8542.1
Top Crypt8492.8
Top Crypt8432.0
Top Crypt8418.9
Top Crypt8338.1
Top Crypt8028.1
Top Crypt7934.0
Top Crypt7855.6
Top Crypt7491.2
Top Crypt6120.6
Top Crypt5465.1
Top Crypt3950.2
Top Crypt3326.3
Adenomas14950.5
Adenomas14791.8
Adenomas12464.6
Adenomas12373.1
Adenomas5351.2
Adenomas4315.1
Adenomas4274.1
Adenomas4078.4
Adenomas4060.6
Tissuem/z
Bottom Crypt / Top Crypt
Bottom Crypt15267.8
Bottom Crypt12654.2
Bottom Crypt9403.6
Bottom Crypt6799.2
Bottom Crypt6081.3
Bottom Crypt5028.9
Bottom Crypt4450.2
Bottom Crypt4004.0
Bottom Crypt3950.2
Bottom Crypt3326.3
Bottom Crypt3298.8
Top Crypt21179.7
Top Crypt16792.9
Top Crypt15995.7
Top Crypt15852.4
Top Crypt13471.6
Top Crypt12435.8
Top Crypt12132.7
Top Crypt10827.2
Top Crypt10387.5
Top Crypt10200.5
Top Crypt10184.6
Top Crypt10166.9
Top Crypt9452.8
Top Crypt9078.3
Top Crypt8655.5
Top Crypt8639.6
Top Crypt8626.2
Top Crypt8492.8
Top Crypt8338.1
Top Crypt7996.9
Top Crypt7934.0
Top Crypt7855.6
Top Crypt6120.6
Top Crypt4981.3
Top Crypt4267.4
Tissuem/z
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Table 4: Proteomic comparisons of ApcMin/+ adenoma and different compartments of normal 
crypts. The WFCCM was used to select the statistically significant peaks that allowed the 
classification of the three groups of samples. The classification accuracies were calculated using 
the leave-one-out cross-validation class prediction method.   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
100%40Adenoma vs. Top of Normal Crypt
100%19Adenoma vs. Bottom of Normal Crypt
classification 
accuracy
No. of differentially 
expressed peaksComparisons
97%77Top vs. Bottom ofNormal Crypt
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into two groups using the top 77 differentially expressed protein markers, achieving 99% 
classification accuracy (figure 19A). For the comparisons of the bottom of normal crypts and 
adenomas, 62 bottom of crypt protein profiles and 78 adenomas protein profiles were clustered 
into two different groups with 100% accuracy using the top 19 protein markers (figure 19B). 
Similarly, 68 top of crypt protein profiles were clustered with 100% accuracy from the 78 
adenomas protein profiles using the top 40 protein markers (figure 19C). All these analyses were 
performed as training cohorts. The red intensity scale bar corresponds to higher protein marker 
expression level and black corresponds to lower protein expression level. Different protein 
expression patterns were clearly shown in the figure 19A-C. The high classification accuracies 
achieved from this method further confirm the validity of the protein markers that were 
differentially expressed among the three groups.  
 
Identification of Differentially Expressed Protein Markers  
To further explore the biological functions of the differentially expressed protein 
markers, the identifications of the selected protein markers were pursued. The schematic 
representation for the protein marker identification strategy is illustrated in figure 20. Briefly, the 
normal colonic crypt and adenomas were homogenized separately and different cell lysates were 
fractionated using reverse phased HPLC. Each HPLC fraction was measured using MALDI MS 
and the fractions containing the proteins with target m/z value were chosen for trypsin digestion. 
The subsequent amino acid sequence analyses of the tryptic peptides were performed using 
capillary LC-MS/MS or nano-ESI MS/MS. The SEQUEST algorithms are used to determine the 
“best fit” between the MS/MS sequence and the information from protein databases [27]. With 
matched amino acid sequences from the MS/MS analyses, the identified protein markers have 
theoretical molecular weights matching the target protein molecular weights considering the post-
translational modifications.  
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Figure 19A: Hierarchical cluster analysis of the top and bottom of normal crypts. Total of 128 out 
of 130 samples were classified correctly using the Eisen’s clustering algorithm with the top 77 
differentially expressed protein markers. 
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Figure 19B: Hierarchical cluster analysis of the ApcMin/+ adenoma and bottom of normal crypts. A 
100% classification accuracy was achieved using Eisen’s clustering algorithm with the top 19 
differentially expressed protein markers. 
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Figure 19C: Hierarchical cluster analysis of the ApcMin/+ adenoma and top of normal crypts. A 
100% classification accuracy was achieved using the Eisen’s clustering algorithm with the top 40 
differentially expressed protein markers. 
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 Figure 20. Schematic representation of protein marker identification process.  
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One example of the protein identification is shown in figure 21. Figure 21A shows the HPLC UV 
(214 nm) trace for the cell lysate prepared from colonic polyps. MALDI MS indicated that 
fraction 26 contained the target tumor-specific proteins (Fig. 21B). The LC-MS/MS sequencing 
of the peptides obtained from trypsin digestion of fraction 26 provided clear evidence for the 
presence of galectin-2, with 4 peptides found constituting 39% of the protein sequence. Figure 
21C shows the observed MS/MS sequence spectra for the peptide [ETLNLHFNPR], a unique 
tryptic peptide to galectin-2. Considering the plausible addition of an acetyl group at the amino-
terminus after removal of the initial methionine, the average molecular weight for galectin-2 is 
14790.8 Da, which matches well with the observed mass for at 14790.5 Da in the protein 
expression profiles.  
Using this approach, six significant protein markers from the normal crypt and adenomas 
comparisons were identified from the cellular homogenates. These identified protein markers are 
serine protease inhibitor kazal type 3 (Spink3), calmodulin, cysteine-rich intestinal protein 
(CRIP), calgranulin A, calcyclin, and galectin-2. Spink3, CRIP, and calmodulin were 
overexpressed in the normal crypt compared to the adenomas, and were more abundant in the top 
of crypts vs. the bottom of crypts. Calgranulin A, calcyclin, and galectin-2 were found 
overexpressed in the adenomas. The average molecular weight, the sequence coverage from the 
MS/MS analyses, the overexpressed region and brief description of the biological functions of 
these protein markers are shown in Table 5.  
 
Immunohistochemistry of Identified Protein Markers 
 Immunohistochemistry was performed to confirm the differential expression of the 
identified protein markers. From the mass spectrometric analysis, CRIP was decreased in 
colorectal adenomas vs. normal crypts. Within the crypts, CRIP was expressed relatively higher 
in the top compartment compared to the bottom compartment. These results were consistent with
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Figure 21: The identification of galectin-2. A). UV trace (214 nm) for the HPLC of the polyp 
homogenate; B) MALDI mass spectra of the fraction which contains the target protein; C) 
MS/MS of the tryptic peptide at m/z 621.1 (z = 2+) of galectin-2. A total of four peptides were 
sequenced for galectin-2 in the trypsin digestion of the HPLC fraction. 
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Table 5: The list of identified protein markers resulted from the comparison between the crypt 
base and adenomas.  
 
 
 
 
 
 
 
 
 
Regulation of various 
enzyme activity by Ca2+Bottom Crypt36% (3)16792Calmodulin
Binds β-galactosideAdenoma39% (4)14791Galectin-2
Interacts with annexin II in a 
calcium-dependent mannerAdenoma34% (3)9961Calcyclin
Regulates immune reactionsAdenoma74% (3)10165Calgranulin A
Intracellular zinc transportBottom Crypt60% (4)8419CRIP
Exhibits anti-trypsin activityBottom Crypt60% (2)6120Spink3
FunctionHigher Expression
MS/MS sequence 
coverage (number of 
sequenced peptides)
Molecular 
Weight (Da)Protein Name
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the immunohistochemical staining for CRIP (Figure 22 A and B). Calcyclin was found to be 
increased in the adenomas vs. normal crypts from direct protein profiling and thus was confirmed 
by the immunostaining results (Figure 22 C and D). Similarly, calgranulin was increased in the 
adenomas vs. normal crypts and the mass spectrometry analysis was consistent with the 
immunostaining results (Figure 22 E and F).  
 
Discussion 
 In this study, epithelial cells from the top third and bottom third compartments of normal 
mouse colonic crypt and adenomatous cells from ApcMin/+ mice polyps were obtained using laser 
capture microdissection. The protein profiles were directly obtained from these microdissected 
cells using MALDI-TOF MS. These profiles were analyzed using WFCCM program and 
statistically significant protein markers for each group were obtained. Using hierarchical 
clustering analysis, the protein profiles from the three groups were accurately classified from each 
other. A set of highly statistically significant protein markers were identified and their differential 
expressions were confirmed with immunohistochemistry.   
 Dividing the crypts into top and bottom compartments for proteomic comparisons with 
adenomas is a critical first step in elucidating protein changes specific to the initial stages of 
colonic neoplasia. The bottom crypt region is widely believed to be the site where colon cancer 
cells initiate due to the stem cells locating in this compartment [54, 55]. The daughter cells 
rapidly proliferate in the bottom crypt and migrate up along the crypt, gradually losing their 
capacity to divide. When these cells reach to the top crypt, they undergo apoptosis and shed into 
the lumen. Any genetic alterations are lost in daughter cells as they consistently move out of the 
crypt. Only the stem cells are in a steady state of cell growth and permanently tethered to a niche 
at the bottom crypt. Oncogenic mutations accumulate in the bottom compartment which is 
considered as the target cells during colonic neoplasia transformation. Therefore, providing the
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Figure 22: The immunohistochemistry results are consistent with the proteomic findings. CRIP 
was expressed higher in the top of the crypt (A) but not in colonic adenomas (B). The presence of 
calcyclin was lower in normal crypts (C) compared to adenomas (D). Calgranulin A expression 
was also lower in normal crypts (E) compared to colonic adenomas (D). The panel (A) and (B), 
(C) and (D), (E) and (F) were from the in same tissue section. The magnification power for (A) 
and (B) were 20X and (C)-(F) were 40X.  
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proteomic pattern specific to the bottom crypt compartment has a significant value in serving as 
an accurate reference for the molecular transition in CRC tumorigenesis.  
In this study, the different protein expression profiles from the top and bottom of normal 
crypts were demonstrated using the WFCCM method and hierarchical clustering method. The 
near perfect classification of the 130 top and bottom crypt protein profiles were achieved using 
both of the statistical methods. This represents the first time that top and bottom crypts can be 
accurately classified from each other based on their proteomic pattern differences.  
Perfect classification was achieved for both cases for the proteomic pattern comparisons 
of adenomas vs. top and bottom of normal crypts. We chose to focus on the comparison between 
the crypt base and adenomas because this comparison is more relevant in elucidating the protein 
markers associated with colorectal tumorigenesis. Both cells at the crypt base and neoplasia cells 
constantly differentiate and proliferate, with the difference being the former is well controlled and 
the latter escapes apoptosis regulation. Thus, the protein markers derived from this comparison, 
as shown in Figure 19B, hold promise in revealing protein markers specific to highly proliferative 
cells which also are malignant.  
Some of the statistically significant protein markers were identified through sequence 
analyses using tandem mass spectrometry. Their differential expressions were further confirmed 
using immunohistochemistry. Protein markers overexpressed in colonic neoplasia are also in 
agreement with literature. For example, calcyclin, found up-regulated in the ApcMin+/- adenomas in 
this study, has also been reported as overexpressed in human colonic neoplasia [66, 67]. 
Calcyclin belongs to the S100 protein family and contains two EF-hand calcium-binding motifs. 
It has been implicated as being involved in cell regeneration [68], differentiation [69], and 
metastasis [70, 71]. Calcyclin also has been suggested to play a role in intracellular calcium 
homeostasis, signaling and ion transport [72]. The overexpression of calcyclin has been reported 
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in human melanoma [70], squamous cell carcinoma of the oral mucosa [73] and human breast 
cancer [74]. 
Another S100 protein found upregulated in the ApcMin+/- adenomas is calgranulin A, 
whose overexpression has also been reported in previous proteomic study in azoxymethane-
treated mouse colorectal tumor [75] and human colorectal cancer [76]. Our immunostaining 
confirms its elevated expression in the ApcMin+/- colonic adenomas. Calgranulin A binds with 
calgranulin B and forms a complex called calprotectin [77]. As a calcium and zinc binding 
protein, calprotectin is a multipotent molecule and can inhibit several zinc-dependent 
metalloproteinase by sequestration of zinc [78]. Calprotectin is found abundantly in neutrophils 
and monocytes. Calprotectin’s level in plasma, stools or cerebrospinal fluid is increased when 
leukocytes are activated [79]. Patients with gastrointestinal cancers have been found with higher 
fecal calprotectin levels than control patients [80]. Though calprotectin is not a marker specific to 
colon cancer, it is has been routinely used as a marker for patients with inflammatory bowel 
disease in Norway and several other centers in Europe [81].  
Galectin-2 was also found to be overexpressed in the ApcMin+/- adenomas compared to 
normal crypts. Galectin-2 belongs to the galectin family which binds specifically to β-galactos-
containing oligosaccharides [82]. Galactin-1 and galectin-3 have been shown to be upregulated in 
human colon cancer [83], pancreatic tumor [84], and head and neck squamous cell carcinoma 
[85] using immunohistochemistry and western blotting. Increased galectin-3 expression correlates 
with decreased survival in colorectal cancer[86, 87]. Therefore, though the functions of galectin-2 
in CRC have not been studied extensively, it shows a promising role in colorectal carcinogenesis.  
As a valuable discovery tool, LCM combined with MALDI MS technology eliminates 
the need to know in advance the specific proteins that are changed in the comparative analyses. 
Some protein markers which have not been previously reported as associated with CRC were also 
found in this study, including CRIP, SPINK3, and calmodulin. The biological functions of these 
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protein markers need to be further explored for their potential associations with CRC 
development.          
 Some limitations and future developments need to be addressed. First, the identified 
proteomic patterns should be further validated in human colonic polyps. Though ApcMin+/- mice 
polyps have similar genotype and phenotype with human familial adenomatous polyposis (FAP), 
other types of colonic cancer also exist for human colonic malignancies, such as hereditary non-
polyposis colon cancer (HNPCC) and sporadic colon cancer. Whether the protein makers found 
in this study are the same for different types of CRC should be validated. Second, although the 
direct tissue protein profiling approach provides highly accurate and specific protein markers for 
neoplastic cells, it is an invasive technique and limited for patients who have colonic biopsies, 
thus making it difficult to use as a screening tool. However, these neoplastic protein markers 
detected in tissue could degrade into serum or feces. Detecting the specific fragments or intact 
protein markers from the serum or fecal matter would be more applicable for colorectal cancer 
screening.  
 In conclusion, our data show that the proteomic difference present within minute tissue 
structure like normal murine crypts can be obtained using LCM and MALDI MS. Colonic 
neoplastic protein markers can be elucidated. Further functional analysis of the biological 
activities of the protein markers will advance our understanding of the colorectal tumorigenesis 
and will assist CRC diagnosis and treatment.  
 
Materials and Methods 
Chemicals  
 Sinapinic acid, ammonium hydrogen carbonate, dithiothreitol, iodoacetamide and 
phenylmethanesulfonyl fluoride (PMSF), were purchased from Sigma (St. Louis, MO, USA). 
Sucrose and Tris were purchased from J. T. Baker (Phillipsburg, NJ, USA). Formic acid (98-
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100%) was from EM Science (Merck, Darmstadt, Germany). Sequencing-grade trifluoroacetic 
acid (TFA) was purchased from Burdick and Jackson (Muskegon, MI, USA) and HPLC grade 
acetonitrile were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Bovine sequence-grade 
trypsin was purchased from Promega (Madison, WI, USA).  
 
 
Laser Capture Microdissection 
A total of four wild-type and eight ApcMin+/- adult mice with C57/Bl6 background were 
used for the protein expression profiles analyses. The ApcMin+/- polyps were a gift from Dr. Joanna 
Groden. The frozen colon and polyps were partially embedded in OCT and five micron frozen 
sections were cut at –15oC using a cryostat. Each tissue section was transferred onto a glass slide 
and immediately dehydrated as followed: 70% ethanol 1 minute, 95% ethanol 1 min, 100% 
ethanol 1 min (2X), xylene 2.5 min (2X) and air dried for 5 min. To investigate the number of 
cells captured per laser shot, a Hematoxylin and Eosin stained section was prepared. The H&E 
sections showed the polyps were advanced adenomas with areas of cribriform architecture 
indicative of high grade dysplasia. The LCM was performed using an Arcturus PixCell II LCM 
system and CapSure caps (Arcturus, Mountain view, CA). The diameter of the LCM laser beam 
was focused at 30 micrometer. The laser was carefully aimed and fired at either the bottom or top 
third of the crypts and the specific cells of interested were microdissected onto the LCM film. 
The adenoma cells from the ApcMin+/- mice were microdissected in the similar manner. 
Approximately 100 cells were microdissected per mass spectrometry analysis.    
 
MALDI MS Sample Preparation and Analysis 
The LCM film with attached cells was gently peeled off from the LCM cap and adhered 
to a MALDI target plate with double-sided tape (Digi-Key, Thief River Falls, MN). Sinapinic 
acid at 20 mg/ml in 5/5/0.3 v/v/v acetonitrile/water/trifluoroacetic acid was used as the matrix 
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solution. Under microscope visualization, the matrix solution was carefully deposited only on the 
captured cells with a pulled glass capillary. The MS analysis was performed in the linear mode 
under optimized delayed ion extraction conditions using a DE-STR MALDI TOF mass 
spectrometer (Applied Biosystems, Framingham, MA). Three hundred laser shots were used to 
generate one mass spectrum from the captured cells. Constant instrumental settings including 
laser energy were used for all the analysis.  
 
Statistical Analysis 
 The mass spectra were baseline corrected, normalized and the peaks were aligned across 
all the acquired mass spectra using custom algorithms developed at Vanderbilt University. 
Statistically significant MS signals were selected based on the Kruskal-Wallis test, Fisher’s exact 
test (dichotomizing the expression level as present or not), the permutation t-test, Significance 
Analysis of Microarrays (SAM), Weighted Gene Analysis (WGA), and the modified info score 
method. The cutoff points for each method were p<0.001, p<0.001, p<0.001, 2.75, 2 and 0, 
respectively. A protein that met at least three of these six selection criteria was selected on the 
final list. The Weighted Flexible Compound Covariate Method (WFCCM) [64] was employed in 
the class-prediction model based on the selected proteins to verify whether the proteomic patterns 
could be used to classify tissue samples into adenoma, crypt tops and crypt bottoms. The 
WFCCM method reduced the dimensionality of the problem by using a new covariate obtained as 
a weighted sum of the most important predictors and combining the most significant proteins 
associated with the biological status from each analysis method.  We estimated the 
misclassification rate using the leave-one-out cross-validation class prediction method based on 
the WFCCM. The agglomerative hierarchical clustering algorithm was also applied to investigate 
the pattern among the statistically significant discriminator proteins as well as the biological 
status using Eisen’s software. 
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Protein Identification 
Three mice were sacrificed by CO2 inhalation and the crypts were isolated from the 
colons as the technique described previously [88]. The isolated colonic crypt pellet (100 mg) was 
suspended in 1ml of homogenization buffer (0.25M sucrose, 0.01M Tris-HCl and 0.1mM 
phenylmethylsulfonyl fluoride) and homogenized with a Duall homogenizer. The lysate went 
through a series of centrifugation steps (10 min at 680 g, 10 min at 10,000g and 1h at 100,000g). 
Then 250 µl of 0.3 M NaCl/0.01 M Tris-HCl solution was used to extract protein of the pellet 
from the 680g centrifugation pellet with multiple bursts of a Kontes motor-driven polyproylene 
pestle for one minute and the solution was centrifuged at 16,000g for ten minutes. All the 
procedures were done at 4°C. 
The supernatant from the 100,000g centrifugation and salt extraction of the pellet was 
further separated with a polymeric reverse phase HPLC column (259VHP5415, Vydac, Hesperia, 
CA). The solvent A was 0.1% trifluoroacetic acid and solvent B was 0.085% trifluoroacetic acid 
in acetonitrile. The flow rate was 1 ml/min and the gradient was 5 min at 5% B, then in 75 min to 
60% B, then in 10 min to 95% B. The fractions were collected every minute up to 80 minutes. 
The HPLC fractions containing the proteins which had the target molecular weight were found 
using MALDI mass spectrometry. For trypsin digestion, the HPLC fractions of interest were 
lyophilized and reconstituted with 10 µl of 0.4 M ammonium hydrogen carbonate and 5 µl of 45 
mM dithiothreitol solution, followed by incubation at 60°C for 15 min. The solution was set in 
the dark for 15 min after adding 5 µl of 100mM iodoacetamide. 1 µl of 1 µg/µl modified porcine 
trypsin (Promega, Madison, WI) was added and incubated at 37oC for 4h. The tryptic peptides 
were sequenced with nanoelectrospray MS/MS using an MDS SCIEX Qstar QTOF mass 
spectrometer (Applied Biosystems, Toronto, Canada). For the fractions containing complex 
protein mixtures, the tryptic peptides were sequenced using capillary LC-MS/MS with LCQ Deca 
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(ThermoFinnigan, San Jose, CA) and the sequenced peptides were searched using the SEQUEST 
algorithm.  
For the identification of adenoma markers, 300 mg of the polyp was homogenized and 
centrifuged according to the procedure described above. The nuclear fraction was extracted with 
450 µl of 0.3M NaCl solution. 400 µl of the salt extract solution was separated over a C4 Vydac 
column (214MS5215) at 40 °C using the Waters HPLC system. Using the same mobile phase 
described above, the gradient started from 5% B for 5 min, to 25% B in 15 min, then to 70%B in 
55 min, and finally to 95% B in 10 min. The fractions were analyzed using the protocol described 
above.  
 
Immunohistochemistry 
 Five micron sections of paraffin-embedded tissues were placed on charged slides and the 
paraffin removed. The sections were rehydrated and placed in heated Target Retrieval Solution 
from DakoCytomation (Carpinteria, CA) for 20 minutes. For calgranulin-A immunostaining, 
endogenous peroxidase was neutralized with 0.03% hydrogen peroxide and samples were treated 
with diluted rabbit serum prior to primary antibody addition.  Tissues were incubated with goat 
anti-Calgranulin A (m-19) from Santa Cruz Biotechnology (Santa Cruz, CA) diluted 1:500 for 30 
minutes.  Sections without primary antibody served as negative controls. The Vectastain ABC 
Elite (Vector Laboratories, Inc) System and DAB+ (DakoCytomation) was used to produce 
localized, visible staining. Slides were lightly counterstained with Mayer’s hematoxylin, 
dehydrated and coverslipped. For the CRIP immunostaining, after the sections were rehydrated 
and placed in heated Target Retrieval Solution (DakoCytomation), endogenous peroxidase 
activity was inactivated with 0.03% hydrogen peroxide followed by a casein-based protein block 
(DakoCytomation) for nonspecific staining blocking.  The sections were incubated with rabbit 
anti-CRIP diluted 1:50 for 120 minutes.  Sections without primary antibody served as negative 
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controls. The Dako Envision+ System, rabbit/HRP (DakoCytomation) was applied for 30 minutes.  
DAB+ was used to produce specific, visible staining.  The slides were lightly counterstained with 
Mayer’s hematoxylin, dehydrated and coverslipped. The immunohistochemistry was performed 
by Kelly Parman at the VUMC Immunohistochemistry Core lab.  
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CHAPTER IV 
 
PROTEOMIC PATTERNS AND PREDICTION OF GLOMERULOSCLOROSIS 
AND ITS MECHANISMS 
 
 
Introduction 
As key structures of kidney nephrons, glomeruli are tiny round structures in the kidney 
cortex composed of capillary blood vessels that are actively involved in the filtration of the blood 
to form urine. The scarring of the glomeruli is referred as glomerulosclerosis, which is a common 
lesion for a variety of renal diseases, such as idiopathic focal segmental glomerulosclerosis 
(FSGS). The incidence of FSGS is increasing and the recurrence rate is high for post renal 
transplantation, making it one of the primary glomerular diseases. Progression of FSGS is 
postulated to develop from early diffuse podocyte injury preceding overt sclerosis [89, 90], likely 
involving multiple complex mechanisms. With the advancement of proteomic techniques [91, 92], 
simultaneous examination of hundreds of proteins related to kidney disease holds promise in 
unraveling novel underlying mechanisms of progression and thus identifying possible targets for 
intervention in FSGS.  
 The focal segmental nature of sclerosis raises the question of whether the remaining 
nonsclerotic glomeruli at a given time point in FSGS already are programmed to sclerotic 
pathways, or alternatively have less prosclerotic activation and thus may be more susceptible to 
therapy. We therefore sought to examine proteomic profiles from the nonsclerotic glomeruli in 
the FSGS kidney, and compare to normal baseline and glomeruli with established sclerosis. The 
following specific aims are developed for this application:  
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Specific Aim 
 To obtain proteomic patterns to begin classifying glomerulosclerosis at the protein level 
and to advance the understanding of glomerulosclerosis mechanisms.  
 
Results 
Protein Profiles of Normal, Non-sclerotic and Sclerotic Glomeruli 
 LCM allowed precise dissection of only glomeruli without surrounding tissue under 
LCM phase microscopy from surrounding cortex under LCM microscope without staining, as 
shown in (Figure 23). Each MALDI mass spectrum was obtained from an average of five 
microdissected glomeruli (~200 cells) averaging signals from 250 consecutive laser shots. From 
the six rats, a total of 60, 30, and 60 mass spectra were obtained from the normal, nonsclerotic 
and sclerotic glomeruli, respectively. Approximately two hundred protein signals were detected 
per spectrum in the mass range of 2,000-70,000 Da, with the signals under 20,000 Da yielding the 
best resolution. Differentially expressed signals were found among the three different classes of 
glomeruli, as shown in Figure 24.  
 
Glomerular Proteomic Pattern Comparisons  
 Total of 1473 distinct peaks across all the spectra were obtained. Using the weighted 
flexible compound covariate method (WFCCM) statistical analysis, we were able to classify the 
normal and sclerotic glomeruli proteomic pattern with 99.2 % accuracy using the top 102 
differentially expressed MS signals. Similarly, 96.7% classification accuracy was obtained for the 
comparison of normal glomeruli vs. nonsclerotic glomeruli using the top 166 differentially 
expressed MS signals. A classification accuracy of 97.8% was obtained for nonsclerotic 
glomeruli from sclerotic glomeruli using the top 84 differentially expressed MS signals (Table 6).  
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Figure 23. The process of laser capture microdissection of a normal glomerulus. A). The normal 
glomerulus can be clearly recognized. B). The remaining tissue section after the glomerulus was 
microdissected. C). The microdissected glomerulus on the LCM film. Each microdissected 
glomeruli section contains approximately 50 cells.   
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Figure 24. Mass spectra obtained from three groups of glomeruli: A) normal baseline glomeruli, 
B) nonsclerotic glomeruli, and C) sclerotic glomeruli.  
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Table 6. The weighted flexible compound covariant method (WFCCM) was used to select the 
statistically significant peaks that allowed classification of the three groups of samples according 
to their proteomic patterns. The misclassification rate was calculated using the leave-one-out 
cross-validation class prediction method[64].  
 
 
 
 
 
< 0·00012 (97.8)84Non-sclerotic Glomeruli (30) 
vs. Sclerotic Glomeruli (60)
< 0·00013 (96.7)166Non-sclerotic Glomeruli (30) 
vs. Normal Glomeruli (60)
< 0·00011 (99.2)102Normal Glomeruli (60) 
vs.  Sclerotic Glomeruli (60)
Probability of random 
permutations with 
misclassifications
No. of misclassified 
samples (%)
No. of 
differentially 
expressed 
peaks
Classification (sample size)
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 The agglomerative hierarchical clustering algorithm was used to investigate the protein 
expression patterns among the significant differentially expressed proteins with Eisen’s software. 
The selected proteomic pattern distinguished all the normal glomeruli from nonsclerotic 
glomeruli with 100% classification accuracy. A classification accuracy of 99.2% was obtained in 
distinguishing normal vs. sclerotic glomeruli and 92.2% classification accuracy for nonsclerotic 
glomeruli vs. sclerotic glomeruli (Figure 25). The overall proteomic pattern of nonsclerotic 
glomeruli was more similar to sclerotic than to normal glomeruli (P<0.0001).  
 
Identification of Thymosin β4 and Its Expression In Vivo and In Vitro 
The protein markers that statistically most significantly contributed to differential 
classification of our three classes of glomeruli were targeted for identification. After the tissue 
homogenization and HPLC separation steps, three fractions containing the peak of m/z value 
4963.76, one of the target proteins, were found using MALDI MS (Figure 26A). With LC-
MS/MS analysis of the resulting tryptic peptides, thymosin β4 was identified as the target protein 
marker. Multiple MS/MS spectra were found to be consistent with the thymosin β4 tryptic 
peptides: [TETQEKNPLPSK]20-31, [KTETQEKNPLPSK]19-31, [TETQEKNPLPSKETIEQEK]20-38, 
and [KTETQEKNPLPSKETIEQEK]19-38. The sequest cross correlation scores for these sequences 
were 3.42, 3.89, 4.95 and 4.69, respectively, showing a strong correlation between the MS/MS 
spectra and the amino acid sequences. As an example, the MS/MS spectra for 
[TETQEKNPLPSK]20-31  is shown in figure 26B. These sequences composed 44% of the total 
amino acid sequence of thymosin β4. Considering the previous reported N-terminal acetylation 
[33], the theoretical average molecular weight for thymosin β4 is 4963.5 Da, which matches well 
with the target protein molecular weight. The signal intensities of thymosin β4 from the mass 
spectra for normal glomeruli, nonsclerotic glomeruli and sclerotic glomeruli are shown in Figure  
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Figure 25. Hierarchical cluster analysis of three different groups of glomeruli based on the top 
differentially expressed protein patterns. A) Total of 30 non-sclerotic glomeruli and 60 normal 
glomeruli protein profiles were accurately classified; B) One out of 60 normal glomeruli and 60 
sclerotic glomeruli protein profiles was misclassified; C) Seven out of 30 non-sclerotic glomeruli 
and 60 sclerotic glomeruli protein profiles were misclassified. 
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Figure 26. Identification of thymosin β4 as a marker for sclerosis. A) The MALDI mass spectrum 
of a HPLC fraction that contains the target peak at 4963.76 m/z. B) ESI MS/MS spectrum 
consistent with one of thymosin β4’s tryptic peptides, [TETQEKNPLPSK]20-31. 
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27. Thymosin β4 expression levels were increased approximately 3-fold from normal to sclerotic 
glomeruli based on the MS intensities.  
Immunohistochemistry was performed to confirm the increased level of thymosin β4 in 
glomerulosclerosis. Thymosin β4 was increased in sclerotic glomeruli vs. non-sclerotic or normal 
glomeruli (Figure 28). Furthermore, thymosin β4 was found predominantly expressed in 
endothelial cells identified by serial section staining with RECA-1 (Abcam Inc, Cambridge, MA), 
while mesangial cells, stained with anti-rat Thy-1 (BD Pharmingen, San diego, CA) were 
negative for thymosin β4. Podocytes, identified anatomically, and macrophages, double stained 
with ED1 (Biosource) were also negative for thymosin β4.  
Further analyses were performed in vitro assessing thymosin β4 expression in two 
different glomerular cell lines (Figure 29). Western blots from cultured glomerular endothelial 
(GEN) and podocyte cells confirmed endothelial expression of thymosin β4, with no protein 
detected in podocytes. GEN showed a strong immunoreactive band at 4.9 kDa corresponding to 
the expected molecular weight of thymosin β4. Mouse spleen and muscle, used as positive and 
negative controls of thymosin β4 immunohistochemistry and Western blot expression, showed 
expected results.  
 
Thymosin β4 Effect on Sclerosis Mechanisms 
 Whether modulation of thymosin β4 mRNA affected responses to Ang II were assessed. 
Angiotensin stimulates PAI-1 in vivo and in vitro [93, 94]. We therefore assessed PAI-1 
expression in response to Ang II in GEN. To investigate the functional role of thymosin β4 in 
sclerosis, we designed siRNA and control siRNA for thymosin β4 and transfected them into GEN. 
Thymosin β4 protein expression was successfully knocked down by approximately 90% using 
siRNA, with equivalent efficacy of all four siRNAs tested. Scrambled control RNA had no effect. 
We next assessed effect of downregulated thymosin β4 on the Ang II–induced prosclerotic 
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Figure 27: Thymosin β4 intensity levels based on MS signal intensities in the three different 
glomerular groups. Statistical significance of the differences was determined by using a two-
tailed Student’s t test for normal vs. nonsclerotic glomeruli (p <0.01), normal vs. sclerotic 
glomeruli (p < 0.01), and nonsclerotic vs. sclerotic glomeruli (p > 0.05) comparisons. The error 
bars correspond to 95% confidence intervals. 
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Figure 28. Thymosin β4 (brown) was not detectable in normal glomeruli (left), but was increased 
in sclerotic glomeruli (right). Staining was not present in macrophages (red), staining on serial 
sections with endothelial and mesangial markers (not shown) confirmed predominantly 
endothelial localization (anti-thymosin β4, brown; anti-CD68, red).  
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Figure 29: Western blot of thymosin β4 expression in cultured glomerular endothelial cells and 
podocytes. Mouse muscle and spleen tissue were used as negative and positive controls, 
respectively.  
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response, by assessing expression of PAI-1 in these cells. Neither siRNA or control siRNA 
affected baseline PAI-1 expression. Angiotensin II (10-6 M) increased thymosin β4 over baseline, 
and concurrently dramatically upregulated PAI-1 in normal GEN, while transfection with siRNA 
for thymosin β4 significantly decreased the angiotensin II - induced PAI-1 expression. The 
control siRNA had no effect on the Ang II – induced PAI-1 expression (figure 30). 
 
Discussion 
 Our results show that LCM and MALDI-TOF MS can accurately classify the proteomic 
profiles of normal vs. nonsclerotic and vs. sclerotic glomeruli. Using overall proteomic pattern 
similarity comparisons, nonsclerotic glomeruli were found to have more similarities to the 
sclerotic glomeruli than to the normal glomeruli. Thymosin β4 was identified as one of the key 
differentially expressed protein markers upregulated both in nonsclerotic and sclerotic glomeruli 
in the 5/6 nephrectomy model. Immunohistochemistry confirmed thymosin β4 elevated 
expression levels in sclerotic glomeruli, localized particularly to endothelial cells. Using RNAi 
technology, thymosin β4 was found to regulate a key pathway in sclerosis, namely angiotensin II-
induced PAI-1 expression.  
 Normal and sclerotic glomeruli represent the two extremes of evolution of 
glomerulosclerosis. In this study, we confirmed, as expected, that proteomic patterns for these 
normal and sclerotic glomeruli are markedly different. Of greater interest is our finding that 
nonsclerotic glomeruli in the setting of progressive sclerosis also have an altered proteomic 
profile, more closely related to sclerotic than normal glomeruli.  Foot process effacement occurs 
in all glomeruli in FSGS, regardless of whether sclerosis is present in the glomerulus or not. Thus, 
podocyte-related molecules would be expected to be altered in both nonsclerotic and sclerotic 
glomeruli compared to normal baseline. It is likely that such additional proteins, perhaps of 
higher molecular weights, not detected by our LCM and MALDI MS approach, would also be  
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Figure 30: Top: Representative Western blot of replicate experiments of thymosin β4 and Ang II-
induced PAI-1. GEN were stimulated with Ang II (10-6 M) for 24 hours, with or without 
concomitant transfection with siRNA or control siRNA for thymosin β4. Normal GEN at baseline 
expressed thymosin β4 (lane 1), which was successfully knocked down about 90% using siRNA 
(lane 2 and 5 vs lane 3). Neither siRNA nor control siRNA affected baseline PAI-1 expression 
(lane 1 vs lane 2 and lane 3). Ang II dramatically upregulated PAI-1 in normal GEN (lane 4). 
Transfection with siRNA markedly dampened this Ang II induction of PAI-1 (lane 5). Control 
siRNA had no effect (lane 6). Bottom: Average PAI-1 protein expression of replicate Western 
blot experiments, normalized to β-actin. 
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differentially upregulated in both nonsclerotic and sclerotic glomeruli vs. normal. However, 
podocyte effacement does not per se correlate with progressive sclerosis. In human disease, both 
FSGS and minimal change disease (MCD) are characterized by diffuse foot process effacement. 
However, nonsclerosis develops in MCD, and prognosis is excellent, in contrast to the 
progressive scarring of FSGS [89]. In small human renal biopsies, it may be difficult to 
differentiate between MCD vs. FSGS, if the defining segmental sclerotic lesion is not sampled. 
Differential downregulation of GBM α- and β-dystroglycan by immunostaining in MCD, but not 
FSGS, has been proposed as a tool for distinction of these two entities [95]. We hypothesize that 
increased thymosin β4 may be an additional such marker to allow identification of early sclerotic 
processes.  
 Our data further indicate that the nonsclerotic glomeruli in FSGS not only have foot 
process effacement, but also have activation of prosclerotic mechanisms. Our data thus has 
important implications for therapy, as it suggests that these glomeruli are further activated 
towards sclerosis than standard light microscopy and electron microscopy would suggest, and 
more targeted, aggressive therapy might be needed to effect remission or even regression of 
sclerosis [90].  
 The identification of the differentially expressed protein markers in the early, prosclerotic 
stage of progression could advance our understanding of pathomechanisms and possibly direct 
such therapies. As more 5/6 Nx kidney sample become available, more of the top protein markers 
could be identified. Currently, with limited tissue left for protein extraction after the LCM 
experiment, we found by proteomic analysis thymosin β4 expression levels was found to be 
elevated in sclerotic and nonsclerotic glomeruli vs. baseline. This upregulation of thymosin β4 
was further confirmed to be localized to endothelial cells by immunohistochemistry in vivo and 
cell culture analyses. Thymosin β4 is a highly conserved protein which has a wide range of 
functions. Thymosin β4 is an intracellular G-actin sequestering proteins [96], and plays a role in 
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wound healing, angiogenesis, and endothelial cell differentiation [97]. Recently, thymosin β4 was 
reported to increase plasminogen activator inhibitor 1 (PAI-1) expression at both the mRNA and 
protein levels in endothelial cells [98]. PAI-1 inhibits tissue-type plasminogen activator (t-PA) 
and urokinase-type plasminogen activator (u-PA), preventing the activation of plasminogen to 
plasmin, which further degrades not only fibrin, but also extracellular matrix (ECM) [99]. PAI-1 
also inhibits u-PA-induced matrix metalloprotease-2, thus further inhibiting ECM degradation. 
PAI-1 is induced by angiotensin II in vivo and in vitro, and is tightly linked to glomerulosclerosis 
[100]. Conversely, PAI-1 downregulation is linked to amelioration or even regression of 
glomerulosclerosis [90]. Therefore, upregulation of thymosin β4 could promote the 
glomerulosclerosis process via upregulation of PAI-1. 
 To further explore the role of thymosin β4 in this sclerotic pathway, we modulated its 
expression in cultured endothelial cells.  Downregulation of thymosin β4 by RNAi technology 
decreased angiotensin II-induced PAI-1 expression. These findings imply that thymosin β4, via 
effects on PAI-1, is not only a marker, but potentially a contributor, to glomerulosclerosis. Thus, 
thymosin β4 could be another novel target for treatment of glomerulosclerosis. 
  In conclusion, using laser capture microdissection combined with MALDI mass 
spectrometry technology, specific proteomic patterns were obtained that accurately classified 
normal vs. non-sclerotic or sclerotic glomeruli in FSGS. The proteomic pattern of nonsclerotic 
glomeruli in a fibrosing kidney was found to be more similar to the proteomic pattern of sclerotic 
glomeruli than to normal glomeruli, suggesting that non-sclerotic glomeruli have early activation 
of prosclerotic mechanisms. As a discovery tool, our proteomic study further found thymosin β4 
to be a key protein marker of glomerulosclerosis and possibly even a contributor to progression 
by promoting angiotensin-induced PAI-1 expression.  
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Materials and Methods 
Remnant Rat Kidney Model 
 Adult male Sprague Dawley rats (n=6, 250-300g, Charles River, TN, USA) were studied. 
Rats were housed under normal conditions with a 12-hour light/dark cycle, at 70°F with 40% 
humidity and 12-air exchanges/hour and received normal rat chow and water ad lib (“5001” diet, 
Purina Laboratory Rodent diet, 23.4% protein, 4.5% fat, 6.0% fiber, 0.40% sodium).  Rats 
underwent 5/6 nephrectomy under pentobarbital anesthesia by right unilateral nephrectomy (Nx) 
and ligation of branches of the left renal artery, producing a total of 5/6 renal ablation. Focal 
segmental glomerulosclerosis was well developed by 12 weeks after 5/6 Nx, and rats were then 
sacrificed. Glomerulosclerosis was defined as collapse and/or obliteration of glomerular capillary 
tuft accompanied by hyaline material and/or increase of matrix [101]. Nephrectomized right 
kidneys obtained at baseline were used as normal control. A limited number of nonsclerotic 
glomeruli with normal histology were present in the remnant kidneys.  
 
Laser Capture Microdissection 
 Protein profiles were obtained directly from laser capture microdissected cells using 
MALDI MS [51]. Frozen kidney samples from 5/6 Nx or normal baseline were partially 
embedded in OCT and 5 µm thick cryostat sections were cut. The tissue sections were mounted 
on regular glass slides and dehydrated as follows: 70% ethanol 30s, 95% ethanol 1 min, 100% 
ethanol 1 min (2 times), xylene 2.5 min (2 times), and air dried. Rat kidney glomeruli were easily 
identified and classified as normal vs. sclerotic. Glomeruli were identified by phase microscopy 
as 1) normal in baseline kidney, and as 2) sclerotic or 3) nonsclerotic in 5/6 Nx. Glomeruli from 
each category were then microdissected using the Arcturus PixCell II LCM system (Mountain 
View, CA, USA) with a focused 30 µm laser beam. These three groups of glomeruli were 
captured separately onto different LCM caps (Mountain View, CA, USA). On average 50 normal 
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glomeruli were captured from the control right kidney obtained during nephrectomy for each rat. 
From the remnant kidneys 12 weeks after 5/6 nephrectomy, 30 non-sclerotic and 50 sclerotic 
glomeruli were obtained from each rat using LCM. Nonsclerotic glomeruli were obtained from 5 
of the 6 rats because one rat did not have sufficient nonsclerotic glomeruli present in the ablated 
kidney. All 6 rats with 5/6 Nx had sufficient sclerotic glomeruli for LCM analysis. 
 
MALDI Mass Spectrometry  
 Protein expression profiles can be directly obtained from laser microdissected cells using 
MALDI MS [51]. The LCM thermoplastic films with captured cells were peeled off from the 
LCM cap using forceps and mounted on a MALDI target plate using a conductive double-sided 
tape (Digi-Key, Thief River Falls, MN, USA). Sinapinic acid (Sigma, St. Louis, MO, USA) 
solution (20 mg/ml, 50/50/0.3, v/v/v, acetonitrile/water/TFA,) was microspotted on the captured 
cells under microscope visualization using pulled fine glass capillaries. Upon solvent dehydration, 
the matrix and proteins co-crystallized together. MALDI MS analyses were performed in the 
linear mode under the optimized delayed extraction condition on an Applied Biosystems DE-STR 
Voyager mass spectrometer (Framingham, MA, USA).  The crystals was irradiated by a series of 
pulsed laser (λ = 337nm) in a high vacuum. The protein analytes were desorbed and ionized from 
the surface of the tissue forming predominately singly charged protonated ions of the form 
[M+H]+, where M was the protein molecular weight. The protein ions were accelerated in a 
constant electric field and subsequently separated in a time-of-flight (TOF) mass analyzer. The 
mass-to-charge (m/z) ratio of each protein ion was recorded at the detector. Each mass spectrum 
was obtained averaging signals from 250 consecutive laser shots from five microdissected 
glomeruli. After internal calibration, the mass spectra were baseline subtracted and normalized 
using the software developed in our laboratory prior to statistical analysis. 
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Protein Identification 
 Remaining frozen rat kidney cortex (114 mg) samples from the same samples 
investigated by LCM were homogenized in 500 µl of protein extraction buffer using an ice-
chilled Duall glass homogenizer. The protein extraction buffer is composed of 0.25 M sucrose 
(J.T. Baker, Phillipsburg, NJ, USA), 0.01 M Tris-HCl (J.T. Baker) and 0.1mM PMSF (Sigma). 
The homogenate was centrifuged according to the following sequence: 10 minutes at 680g, 10 
minutes at 10,000g, and 1 hour at 100,000 g. The final supernatant was filtered using a Millipore 
Ultrafree-MS 30,000 NMWL centrifugal filter device (Bedford, MA, USA). A volume of 150 µl 
filtrate was separated on a Vydac 259VHP5415 polymeric column (Hesperia, CA, USA) at 40°C 
using a Waters Alliance HPLC system (Milford, MA, USA). Solvent A contained 0.1% TFA 
(Burdick and Jackson, Muskegon, MI, USA) in water and solvent B contained 0.085% TFA in 
acetonitrile (Fisher Scientific, Fair Lawn, NJ, USA). A flow rate of 1 ml/min was used with a 
gradient started from 5% B for 5 min, then in 55 min to 60% B, then in 10 min to 95% B and hold 
at 95% B for 10 min. The fractions were collected every minute and then completely dried using 
Thermo Quest Savant Speedvac (Holbrook, NY, USA). Dried HPLC fractions were reconstituted 
in 10 µl of 5/5/0.3, v/v/v, acetonitrile/water/TFA and analyzed by MALDI-TOF MS.  
The fractions containing target protein markers, as identified by statistical analysis (see 
below) from LCM samples were completely lyophilized again and reconstituted with 10 µl of 
0.4M ammonium hydrogen carbonate (Sigma). These fractions were reduced with 5µl of 45mM 
dithiothreitol (Sigma) in incubation at 60°C for 15 min, followed by alkylation with 5 µl of 
100mM iodoacetamide (Sigma) in the dark for 15 min. One microliter of 1 µg/µl sequencing-
grade trypsin (Promega, Madison, WI, USA) was added, and the digestion allowed proceeding 
for 4 hours at 37°C.  
 The digested fractions were subjected to LC-MS/MS analysis using a ThermoFinnigan 
LTQ mass spectrometer (San Jose, CA, USA). Two microliters of sample were loaded into a 100 
 
 
 
89
µm i.d. self-packed micro-capillary reverse phase column packed with Monitor C18 -Spherical 
Silica from Column Engineering Inc (Ontario, CA, USA). The mobile phase A was 0.1% formic 
acid (EM Science, Darmstadt, Germany) in water and phase B was 0.1% formic acid in 
acetonitrile. The gradient for mobile phase B started at 0% for 3 min, to 5% in 2 min, to 50% in 
45 min, and to 90% in 5 min. The flow rate at the source was 700 nl/min. The fragment ion mass 
spectra were used to search the National Center for Biotechnology Information (NCBI) rat 
protein database using the SEQUEST algorithm [27].  
 
Immunohistochemistry  
For immunostaining, remnant rat kidney tissue was fixed in 4% paraformaldehyde 
overnight at 4°C, routinely processed and embedded in paraffin. Four micrometer sections were 
treated with 3% hydrogen peroxidase for 10 min, Power block (BioGenex Laboratories, San 
Ramon, CA) for 45 mins, incubated with primary rabbit anti-thymosin β4 antibody (Biodesign, 
Saco, ME) for 1 hour at 37°C, and rinsed twice with PBS. HRP conjugated-swine ant-rabbit 
antibody (Dako, Carpenteria, CA) was added and incubated for 45 mins at RT. After rinsing 3 
times with PBS, diaminobenzidene was added as a chromagen. Slides were counterstained with 
hematoxylin.  
Infiltrating macrophages were detected with double staining for thymosin β4 and mouse 
monoclonal antibody to ED1 (BioSource International, Camarillo, CA), a macrophage marker, 
followed by biotinylated goat anti-mouse IgG (BioGenex) for 30 min and alkaline phosphatase-
streptavidin conjugate (BioGenex) for 30 min. Sections were developed with sigma fast red 
TR/Naphtol AS-MX for 5 min, then counterstained and cover-slipped. Negative controls omitting 
the primary antibody and using nonspecific immunoglobulin showed no staining. Positive control 
using rat spleen showed the expected distribution of thymosin β4 [102]. Glomerular endothelial 
cells and mesangial cells were identified on serial sections by immunostaining with anti-RECA-1 
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antibody (Abcam, Cambridge, MA) and mouse anti-rat CD90 (Thy-1) antibody (BD Pharmingen, 
San Diego, CA), respectively.  
 
Cell Culture  
Glomerular endothelial cells (GEN), derived from SV40 mice (gift from Dr. Michael 
Madaio) were grown in 10% fetal bovine serum (FBS) which had been heat-inactivated at 56oC 
for 1 hour, with DMEM:Ham F12 media (low glucose DMEM, 6mM) in a 3:1 ratio, with L-
glytamin 2mM and HEPES 10mM added [103]. The cells were grown at 37oC, with 5% CO2 
under humid conditions in Corning flasks. The cells showed CD31 expression, confirming 
endothelial cell phenotype. Primary cultures of podocyte were performed as follows: rat kidneys 
were removed and the renal capsules were stripped using autoclaved surgical instruments. The 
cortex was isolated and minced into small pieces with razor blade, and glomeruli isolated by 
sieving (sieve pore size 180 µ X2, 75 µ X1). Glomeruli were then suspended in DMEM/Ham’s F-
12 (2:1) containing 0.2 um-filtered 3T3-L1 supernatant, 5% heated-inactivated FCS, ITS solution, 
and 100u/ml penicillin-streptomycin. The cells were then plated onto collagen type I-coated 
flasks, and incubated at 37oC, room air with 5% CO2. After 4 days, cell colonies began to sprout 
around the glomeruli. Cells showed an epithelial morphology with a polyhedral shape when 
confluency was reached at day 7. The cells were characterized as podocytes by detection of 
podocyte specific markers, synaptopodin and nephrin, by immunofluorescence staining. 
siRNA Design and Transfection 
Control siRNAs and siRNAs (antisense and sense strands) for thymosin β4 (Thym) were 
designed suggested by the manufacture (Invitrogen, San Diego, CA, USA). The sense strand 
sequences for 4 different siRNAs and scrambled controls were as follows: Thym 1 5’-
CCGATATGGCTGAGATCGAGAAATT; Thym 2 5’-GAG AAG CAA GCT GGC GAA TCG 
TAA T; Thym 3 5’-TCA AAG AAT CAG AAC TAC TGA GCA G; Thym 4 5’-GGG AGA 
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TGA TGA AAT AGA GAG GAA A; control Thym 1 5’-CCG GGT AAG TCC TAG AGA GAT 
AAT T; control Thym 2 5’-GAT CCA TGC AGC GTA TCC GAT GAA T; control Thym 3 5’-
TCA TAA GAG ACA TCA AGT CGA ACA G; control Thym 4 5’-GGG ATG ATG AAA TAG 
AGA GGA GAA A. In vitro transfections were performed using LipofectaTM 2000 Reagent 
(Invitrogen) according to the manufacturer’s instructions. In brief, GEN were seeded on to 6-well 
plates one day prior to transfection. Transfection with siRNA was done when cells were above 
50% confluent. 100 pmol of siRNA were used for 5 x 105 cells in 2 ml of medium. Cells were 
washed 48 hours after transfection. Angiotensin was used to stimulate GEN as a model of 
sclerosis mechanisms. GEN were stimulated with angiotensin II (Ang II, 10-6 M) for 24 hours, 
with or without concomitant transfection with siRNA or control siRNA. Since all 4 designed 
siRNAs achieved equal downregulation of thymosin β4, only one set of siRNA and its scrambled 
control was used for these experiments. Results were compared to normal GEN as baseline 
control.  
 
Western Blot Analysis  
 For thymosin β4 Western blot analysis, 100 µg of cell lysate from cultured GEN treated 
as above were separated by electrophoresis on 4-20% Tris–glycine gel (BioRad). Equal protein 
loading was confirmed by Coomassie blue staining of duplicate gels after electrophoresis. The 
gels were incubated for 1 hour in phosphate-buffered saline (PBS) containing 10% glutaraldehyde 
(Sigma), washed three times for 20 minutes in PBS, and further incubated in a blotting buffer 
containing 1x Tris-glycine transfer buffer (Invitrogen) and 20% methanol for 30 minutes at room 
temperature. Proteins were transferred to a nitrocellulose membrane (BioRad) by electrotransfer. 
The membrane was pre-incubated for 2 hours in PBS containing 5% skim milk and 0.05% Tween 
20 (PBS-T), incubated for 1 hour at RT in PBS-T with specific antibody (rabbit polyclonal anti-
thymosin β4, 1:1000; Biodesign), washed x5 with PBS-T and incubated with horseradish 
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peroxidase–conjugated secondary antibody (Amersham Biosciences, Buckinghamshire, UK) for 1 
hour at RT. The membranes were washed x5 with PBS-T, and bound antibody was detected with 
an enhanced chemiluminescence detection kit (Amersham Biosciences). Mouse spleen and 
muscle tissues were used as positive and negative controls, respectively.  
For Western blot analysis of plasminogen activator inhibitor-1 (PAI-1), GEN cell lysate 
was separated by electrophoresis on 10% Tris–glycine gel (BioRad). After the transfer of protein, 
the membrane was incubated with antibody specific for sheep anti-mouse PAI-1 antibody (1:250, 
American Diagnostica Inc. Greenwich, CT). After incubation with horseradish peroxidase (HRP)-
labeled anti-sheep IgG secondary antibody (1:1000 dilution in 5% milk TBS-T), the protein bands 
on Western blots were visualized as above and developed on film. The membranes were 
restripped for beta actin, used as a housekeeping control protein (Sigma) [94]. 
 
Statistical Analysis  
 The primary objectives of this study were to identify protein patterns that correlate with 
biological groups and assess the protein patterns closeness among three biological groups.  The 
statistical analyses for identifying a set of proteins expressed differentially between biological 
groups were focused on the following steps: (1) the selection of important proteins that were 
differentially expressed among the study groups. The selection was based on Kruskal-Wallis test, 
Fisher’s exact test (dichotomize the expression level as present or not), permutation t-test, 
Significance Analysis of Microarrays (SAM)[104], Weighted Gene Analysis (WGA)[105], and 
the modified info score method [106, 107]. The proteins were ranked based on the results from all 
these six methods.  (2) The Weighted Flexible Compound Covariate Method (WFCCM)[22, 108-
110] was employed in the class-prediction model based on the ranked proteins to verify whether 
the proteomic patterns could be used to classify study samples into two classes according to the 
chosen parameter, e.g., normal vs. non-sclerotic. The WFCCM method was designed to combine 
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the most significant proteins associated with the biological status from each analysis method, and 
it reduced the dimensionality of the problem using a new covariate obtained as a weighted sum of 
the most important predictors.  We estimated the misclassification rate using leave-one-out cross-
validated class prediction method based on the WFCCM. (3) The agglomerative hierarchical 
clustering algorithm was applied to investigate the pattern among the statistically significant 
discriminator proteins as well as the biologic status using M. Eisen’s software [65]. 
 The statistical analyses for assessing the profile closeness between biological groups 
were focused on the following steps: First, the profile difference between two biological groups 
was measured using the Weighted Gene Analysis method for each individual protein.  This 
method is based on the between and within group Euclidean distance.  After the profile difference 
was estimated, the assessment of the overall closeness among three biological groups was 
completed using the restricted/residual maximal likelihood (REML)-based mixed effect model to 
test the significance of the closeness among three groups.   
 The comparison of quantitative analysis of thymosin β4 among three classes of glomeruli 
was completed using the General Linear Model (Analysis of Variance) to test the mean difference.  
The p-values as well as the 95% Confidence Interval (CI) were reported.  All the tests of 
significance were two-sided, and the differences were considered statistically significant when p-
value < 0.05  
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CHAPTER V 
 
PROTEOMIC PATTERNS OF TUMOR SUBSETS IN HUMAN BREAST CANCER 
 
Introduction 
 Breast cancer is the second leading cause of cancer-related deaths in women of the 
western world. Early-stage breast cancer diagnosis is a major reason for improvement in the 
breast cancer mortality rate. Development of low grade invasive mammary carcinoma is likely a 
sequential progression starting with alterations in normal mammary epithelium, resulting in 
atypical ductal hyperplasia (ADH), which may progress to low grade ductal carcinoma in situ 
(DCIS), and culminating in invasive mammary carcinoma (IMC). High grade DCIS is accepted 
as the precursor of high grade invasive mammary carcinoma; however, the intermediary 
preneoplastic lesions between normal mammary epithelium and high grade DCIS are essentially 
unknown. Thus mammary tumorigenesis is postulated to occur along at least two pathways, 
which may be largely independent. Invasive mammary carcinomas of any grade may also acquire 
the capacity for distant metastasis to other organs [111].  
Normal mammary epithelium is composed of a single layer of luminal epithelial cells 
which sit above a layer of myoepithelial cells and line normal mammary ducts and lobular units 
(Figure 31A). By definition, DCIS consists of a monotonous tumor cell population completely 
filling but confined to basement membrane bound ducts and lobular units and measuring at least 
3.0 mm in size.  Practically speaking, minimal DCIS are usually 5-8 mm and low grade, where as 
high grade DCIS are often 2.0-5.0 cm or more (Figure 31B). When mammary carcinoma has 
achieved the capacity for invasion, tumor cells infiltrate the stroma compartment of the breast. 
The DCIS is accepted as the precursor of IMC (figure 31C), based on its common 
concurrence with IMC and its high rate of recurrence as an invasive tumor at the original site 
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when incompletely excised. The transition from DCIS to IMC is a critical event in the 
development of mammary neoplasia. In women with untreated DCIS, death is a much later event 
than in women with invasive cancer. The natural history of DCIS also demonstrates that in some 
cases the capacity for invasion is never achieved, because when DCIS is present alone, it is 
completely curable by local excision [112]. By defining the protein alterations which can 
distinguish DCIS (lesions which by definition lack the capacity for invasion) from IMC (lesions 
which by definition are invasive), protein markers characteristic of invasion can be elucidated.  
  The heterogeneous nature of most tissues poses great challenges for traditional 
proteomic approaches. Mammary ducts and lobular units represent a relatively small proportion 
of normal mammary tissue, which is dominantly adipose tissue and fibrous stroma. Similarly, 
nests of infiltrating mammary carcinoma cells are usually mixed with desmoplastic stroma and 
inflammatory cells.  Direct tissue protein profiling using combined laser capture microdissection 
and MALDI mass spectrometry is a powerful technology for the rapid and precise discovery of 
protein markers in complex tissues. This combination of techniques permits simultaneous 
examination of hundreds of proteins from a nearly pure cell population removed from a 
heterogeneous sample. Direct analysis of proteomic patterns among IMC, DCIS, and normal 
mammary epithelium by MS has the potential to rapidly address changes that control the 
heterogeneous biology of breast cancer. Comparing the protein profiles of normal mammary 
epithelium, DCIS, and IMC should identify unique protein signatures characterizing each of these 
classes. Subsequent identification of the component proteins should lead to the discovery of novel 
targets for new preventative and therapeutic strategies as well as enhance our understanding of 
mammary tumorigenesis.    
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Figure 31. Breast cancer progression from normal lobular units & ducts (A) to ductal carcinoma 
in situ (DCIS) (B) and to invasive mammary carcinoma (C). The heterogeneous nature of  the 
breast cancer tissue requires the microdissection of specific cells of interest for comparative 
proteomic analysis.  
Non-invasive breast 
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Invasive breast cancer 
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Specific Aim 
 To differentiate human breast tumor from normal breast tissue based on their proteomic 
patterns and begin to distinguish in situ from invasive cancer at the protein level to aid breast 
cancer diagnosis.  
 
Results 
 
Reproducibility and Precision of Protein Profiling  
 The tissue samples were collected from four different centers by way of the Cooperative 
Human Tissue Network (CHTN). First, we wanted to determine if slight but inevitable 
differences in specimen procurement and handling would affect the protein profiling. We 
performed a data agreement analysis based on four examples of normal mammary tissue procured 
from each of the four centers. For each individual specimen included in the data agreement 
analysis, three separate protein profiles were generated from microdissected normal mammary 
epithelium and designated as A, B, and C, for a total of 48 representative MALDI-MS profiles. 
After internal calibration, baseline subtraction and intensity normalization, we compared all peaks 
in these three independently obtained spectra by pairwise comparison and determined the 
percentage intra-sample agreement. Data agreement analyses demonstrated 84% individual intra-
sample agreement with an 86.7% overall intra-sample agreement rate. Similarly, we wanted to 
compare the intra-sample variability across collection centers. These analyses showed intra-
sample agreement across centers to be essentially the same as the overall intra agreement rate.  
Variance component analysis based on a mixed effect model examining the intra-sample variation 
with respect to total variation demonstrated an intra-class correlation coefficient (ICC = inter-
sample variation/inter-sample variation + intra-sample variation) of >70% in the 2500 Da to 25 
kDa range.   
 
 
 
98
Protein expression profiles of normal mammary tissue and breast tumor  
 Protein expression profiles were generated from 88 examples of normal mammary 
epithelium (obtained from reduction mammoplasty specimens), 30 examples of DCIS and 92 
examples of IMC. These specimens were from 196 women. In 14 cases both IMC and DCIS were 
microdissected from the same biopsy. Thirteen DCIS cases were obtained from women with 
concurrent IMC but their IMC was unavailable for dissection, while 3 cases were from women 
with DCIS only. All these specimens were microdissected using LCM by a board-certified 
pathologist (Melinda Sanders, M.D.). For each patient, approximately 500-1000 cells were 
captured and an average of three mass spectra was obtained. The multiple spectra from each 
patient were averaged as one spectrum. Approximately 200 peaks were detected per spectrum and 
more than 1600 signals were detected across all spectra obtained from the 196 patients. 
Representative spectra from three different tissue classes are shown in Figure 32, displaying the 
protein profiles of microdissected normal mammary epithelium, DCIS and IMC from the m/z 
range of 3,200 to 70,000. Asterisks mark the differentially expressed protein peaks between the 
normal, DCIS and IMC samples, showing that there are detectable differences in protein 
expression between the different tissue classes.   
 
Normal Mammary Tissue, DCIS and IMC Classification  
 Using the weighted flexible compound covariate method (WFCCM) and hierarchical 
clustering analyses, the following proteomic pattern comparisons were performed: 1) Breast 
tumor (IMC and DCIS) vs. normal mammary epithelium; 2) IMC vs. normal mammary 
epithelium; 3) DCIS vs. normal mammary epithelium; 4) IMC vs. DCIS.  
 First, for the breast tumor vs. normal mammary epithelium comparison, 92 IMC and 30 
DCIS cases were combined into a single group as mammary carcinoma and compared with the 88  
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Figure 32. Differences in protein expression patterns among patients with normal mammary 
epithelium, ductal carcinoma in situ (DCIS) and invasive mammary carcinoma (IMC) can be 
successfully detected. Three mass spectra from each sample type were averaged to produce the 
profiles. Asterisks (*) mark the proteins differentially expressed among IMC, DCIS and normal 
mammary epithelium.  
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examples of normal mammary epithelium. The 210 samples were equally but randomly divided 
into training and testing cohorts, with 61 tumors and 44 normal samples in each cohort. The 
tumor group in each cohort consisted of 15 cases of DCIS and 46 cases of IMC. When IMC and 
DCIS were dissected from the same specimen, they were assigned to different cohorts. Figure 33 
shows the remarkably high accuracy with which the class prediction model can distinguish breast 
tumor (IMC & DCIS) from normal mammary epithelium based on increasing numbers of 
discriminatory peaks. The x-axis represents the number of discriminator peaks and the y-axis 
represents the classification accuracy. Using the top 50 differentially expressed peaks, the class 
prediction model classified tumors (IMC&DCIS) vs. normal mammary epithelium with 95% 
accuracy in the training cohort and 88% accuracy in the testing cohort.  
 Hierarchical clustering analyses of the training cohort showed accurate segregation of the 
tumor vs. normal samples to opposite ends of the dendrogram and visualized the proteomic 
pattern distribution (figure 34). IMC perfectly segregated from normal breast. DCIS was 
interspersed among IMC but tended to cluster at one end of the tumor bracket.  IMC clustered 
roughly by grade, but interestingly the low grade cancers clustered in the center of the 
dendrogram. One of the two misclassified DCIS could be explained by a technically difficult 
dissection which may have been contaminated by inflammatory cells and stroma. The other 
example of DCIS had been poorly visualized at the time of dissection and was determined not to 
represent DCIS. One of the misclassified normal specimens was later determined to have been 
normal tissue adjacent to tumor.  
 Next, the 92 IMC and the 88 examples of normal mammary epithelium were compared. 
Those 180 cases were from different patients and randomly divided into training and testing 
cohorts, with 46 IMC and 44 normal samples in each set. The IMC vs. normal mammary 
epithelium were distinguished with remarkably high classification accuracy by the class 
prediction model based on increasing numbers of discriminator peaks. Using the top 50                           
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Figure 33. Classification accuracy curves for the training and test cohorts after application of the 
class prediction model. Normal consists of 44 examples of normal mammary epithelium from 
reduction mammoplasty specimens in both the training and test cohorts. Using the top 50 
differentially expressed peaks, the class prediction model classified tumors (IMC&DCIS) vs. RM 
with 95% accuracy in the training cohort and 88% accuracy in the testing cohort.  
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Figure 34. Hierarchical cluster analysis of the 61 breast tumors and 44 normal breast specimens in 
the training cohort according to the protein expression patterns of 50 MS signals. The cluster at 
the top shows the similarity in protein expression profiles of the samples. Substantially raised (red) 
expression of the proteins is noted in individual tumor and normal breast samples. Only 3 normal 
and 2 tumor cases out of the 105 cases were mis-classified.  
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differentially expressed peaks, the class prediction model classified IMC vs. normal with 96% 
accuracy in the training cohort and 90% accuracy in the blinded testing cohort (Figure 35). 
Subsequent hierarchical clustering analysis showed accurate segregation of the tumor vs. normal 
samples to opposite ends of the dendrogram using the top 50 protein peaks (Figure 36). From the 
90 samples analyzed, only 1 IMC and 2 normal samples were misclassified.  
 Third, the DCIS and normal mammary epithelium were compared to elucidate patterns of 
protein expression that are characteristic of DCIS. A total of 30 DCIS and 88 examples of 
mammary epithelium cases were compared. Because of the relatively small number of DCIS 
cases, only a supervised analysis was performed and all cases were assigned to a training cohort. 
Using the leave-one-out cross validation method, 96% classification accuracy was archived using 
the top 44 protein markers (Figure 37). The hierarchical clustering analysis showed accurate 
segregation of the DCIS vs. normal samples to opposite ends of the dendrogram using the top 100 
protein markers (Figure 38). From the 118 sample analyzed, only 2 DCIS and 5 normal samples 
were misclassified.  
 Fourth, 92 IMC and 30 DCIS cases were compared and proteomic patterns associated 
with the transition from in situ tumor to invasive tumor were analyzed. All the cases were 
assigned to the training cohort. Using the top 72 differentially expressed peaks, the class 
prediction model classified DCIS from IMC with 80% classification accuracy in the training 
cohort. When the number of discriminator peaks was increased to 260, the classification accuracy 
was 93% (Figure 39). The relatively large number of peaks required to accurately distinguish 
DCIS from IMC indicate, as would be expected, that the protein expression patterns of these two 
classes are very similar in contrast to the proteomic patterns of normal mammary epithelium vs. 
tumor. In addition, both the DCIS group and the IMC groups are somewhat heterogeneous in 
grade. The inclusion of different grades adds complexity to the classification strategy, which also 
explains why a large number of peaks are required to distinguish the 2 classes. The hierarchical  
 
 
 
104
 
 
 
 
   
 
 
 
 
 
 
 
Figure 35. Classification accuracy curves for the training and test cohorts after the application of 
the class prediction model. Total of 44 normal mammary epithelium and 46 invasive mammary 
carcinoma are in both training and test cohorts. Using the top 50 differentially expressed peaks, 
the class prediction model classified tumors IMC vs. Normal with 96% accuracy in the training 
cohort and 90% accuracy in the testing cohort.  
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Figure 36. Hierarchical cluster analysis of the 46 invasive mammary carcinomas and 44 normal 
breast specimens in the training cohort according to the protein expression patterns of 50 MS 
signals. The cluster at the top shows the similarity in protein expression profiles of the samples. 
Substantially raised (red) expression of the proteins is noted in individual tumor and normal 
breast samples. Only 2 normal and 1 tumor cases out of the 90 cases were misclassified.  
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Figure 37. Classification accuracy curves for the classification of normal vs. ductal carcinoma in 
situ. Total of 88 normal mammary epithelium and 30 DCIS were compared. Using the top 50 
differentially expressed peaks, the class prediction model classified tumors DCIS vs. Normal with 
96% accuracy using leave-one-out cross validation method.  
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Figure 38. Hierarchical cluster analysis of the 30 DCIS and 88 normal breast specimens in the 
training cohort according to the protein expression patterns of 50 MS signals. The cluster at the 
top shows the similarity in protein expression profiles of the samples. Substantially raised (red) 
expression of the proteins is noted in individual tumor and normal breast samples. Only 5 normal 
and 2 DCIS cases were misclassified.  
DCISNormal
Top 100
Differentially 
Expressed 
Proteins 
 
 
 
108
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Classification accuracy curves for the classification of IMC vs. DCIS. Total of 92 IMC 
and 30 DCIS were compared. The classification accuracy increased as the number of protein 
markers increases. Using the 255 differentially expressed peaks, the class prediction model 
classified IMC vs. DCIS with 93% accuracy.  
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clustering analysis showed 6 DCIS cases were misclassified (Figure 40). These data are in accord 
with the WFCCM result (Fig 40) that the proteomic patterns of DCIS and IMC share a larger 
number of peaks with each other than either share with normal mammary epithelium. 
 
Protein Marker Identification  
The identification of statistically significant protein markers was pursued to explore the 
biological functions of the differentially expressed protein markers. A schematic representation of 
the protein marker identification strategy is illustrated in figure 20. Briefly, human breast tumor 
tissue was homogenized and the cytosolic fraction from the differential centrifugation was further 
fractionated using reverse phase HPLC. The UV trace at 214 nm recorded the chromatogram 
(Figure 41A). Each HPLC fraction was measured using MALDI MS and the fractions containing 
the proteins with the target m/z values were chosen for trypsin digestion.  
One of the protein markers which showed greater expression in IMC compared to normal 
breast, eluted at 38 min in the chromatogram (Figure 42B). The subsequent amino acid sequence 
analyses of the tryptic peptides were performed using capillary LC-MS/MS and the results were 
analyzed using the SEQUEST algorithm. The MS/MS spectrum on figure 41C confirmed the 
identity of the tryptic peptide [IQYQLVDISQDNALR]32-46 from the SH3 domain-binding 
glutamic acid-rich-like protein 3 (SH3BGRL3). The theoretical molecular weight of SH3BGRL3 
is 10348.5 Da, which matches well with the measured protein molecular weight 10347 ± 2 Da 
when taking into consideration the plausible removal of the initial methionine and subsequent N-
terminal acetylation. Glutaredoxin was similarly identified as a protein showing greater 
expression in the normal breast tissue compared to tumor. The theoretical molecular weight of 
Glutaredoxin is 11686.6 Da, which matches well with the observed protein molecular weight 
11685 ± 2 Da. One tryptic peptide [DCIGGCSDLVSLQQSGELLTR]77-97 was found for this  
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Figure 40. Hierarchical cluster analysis of the 30 DCIS and 88 normal breast specimens in the 
training cohort according to the protein expression patterns of 29 MS signals. 21 IMC and 6 
DCIS cases were misclassified to different clusters.  
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Figure 41. The identification of SH3 domain-binding glutamic acid-rich-like protein 3, a protein 
marker of invasive mammary carcinoma. A) The UV chromatograph of the HPLC separation of 
breast tumor cell lysate. B) The protein of 10346 Da, a protein marker of interest, was found in 
one HPLC fraction. C) The MS/MS spectra were consistent with the tryptic peptides of the target 
protein.    
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protein. Thymosin β4 (4964 Da), Thymosin β10 (4937 Da) and ubiquitin (8564 Da) were also 
identified as highly statistically significant discriminators for IMC vs. normal breast.   
 
Discussion 
 In this study, protein profiles were obtained from a total of 210 human breast carcinomas 
and normal breast tissue using LCM combined with MALDI MS. Statistically significant 
proteomic patterns that accurately distinguished normal mammary epithelium from DCIS and 
IMC were obtained. A set of the statistically significant protein markers were identified using 
tandem mass spectrometry.  
 Selecting the proteomic patterns that can accurately distinguish mammary carcinoma 
(IMC & DCIS) from normal mammary epithelium was our primary goal for this study. Using the 
top 50 statistically significant protein discriminators, mammary tumor could be distinguished 
from normal mammary tissue with greater than 95% accuracy in the training and 88% accuracy in 
the blinded testing cohorts. We further specifically compared the protein profiles of invasive 
mammary carcinoma with those of normal mammary epithelium. These two classes of tissues 
were distinguished with 96% accuracy in the training cohort and 90% in the blinded testing 
cohort. The proteomic patterns of normal mammary epithelium and DCIS were compared to 
elucidate protein markers specific to DCIS suggesting that they may be associated with neoplastic 
transformation. Using the top 47 protein markers, DCIS could be distinguished from normal 
mammary epithelium with greater than 96% accuracy. Finally, we compared the protein profile of 
DCIS to IMC to identify expression differences that are associated with the capacity for invasion. 
Using 255 selected peaks, we distinguished DCIS from IMC with 93% accuracy. The large 
number of protein biomarkers needed to achieve high classification accuracy suggests the 
differences in protein expression between the classes are few. 
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 Identification of differentially expressed protein markers selected from the analyses may 
provide new insights into mechanisms of breast tumorigenesis. Identification of thymosin β4 and 
thymosin β10 were in agreement with previous reports. Increased expression of beta-thymosins at 
the RNA or protein level have been reported in lung cancer [22], breast cancer cell lines [113], 
and colon cancer cell lines [114]. Recent data suggests that thymosin β4, an actin-sequestering 
protein, may play an important role in tumor metastasis and angiogenesis [115]. Cha et al. 
showed that overexpression of thymosin β4 is associated with an increase in the expression of 
vascular endothelial growth factor (VEGF), a known angiogenic factor [116]. In our previous 
study of thymosin β4’s role in glomerulosclerosis, we found that the inhibition of thymosin β4 
dramatically decreased the expression level of plasminogen activation inhibitor-1 (PAI-1) via an 
angiotensin dependent manner. Upregulation of thymosin β4 also increases PAI-1 expression in 
endothelial cells [98]. Interestingly, high expression of PAI-1 in breast cancer is strongly 
associated with aggressiveness and poor outcome [117, 118]. Our results thus suggest that 
thymosin β4 may contribute to breast tumor angiogenesis via the plasminogen activator-plasmin 
system. Glutaredoxin (GRX) and SH3 domain-binding glutamic acid-rich-like protein 3 
(SH3BGRL3), both involved in the regulation of protein redox reactions, were identified as 
differentially expressed between normal mammary epithelium and mammary tumor cells. GRX 
belongs to the ubiquitous glutathione (GSH)-dependent oxidoreductase family, which catalyzes 
the reduction of protein-glutathionyl-mixed disulfides. GRX has various cellular functions, 
including functioning as a redox sensor via interaction with the apoptosis signal-regulating kinase 
1 [119], protection of cells against apoptosis [120], activation of ribonucleotide reductase [121] 
and regulation of different transcription factors [122]. SH3BGRL3 shows significant sequence 
homology with GRX and its overall structural fold matches with the thioredoxin fold [123]. 
SH3BGRL3 is suggested to function as an endogenous modulator of GRX biological activities by 
competitive binding to yet unknown target proteins.  
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 As larger numbers of tumor samples become available, the study of subpopulations 
within the invasive cancer group will be possible. First, the presence of lymph node metastases at 
the time of the primary diagnosis is a significant predictor of relapse and poor outcome. 
Comparing the protein profiles of lymph node positive and lymph node negative cancers may 
identify proteins associated with the capacity for metastasis. Such markers would have significant 
clinical value as they may identify tumors programmed for metastasis before they have spread to 
lymph nodes. A previous proteomic study of lung cancer found two protein markers which were 
highly predictive of lymph node involvement [22].  
 Studying disease outcome in breast cancer is more difficult than other high life-
threatening cancers, such as lung cancer, because relapse-free survival can be prolonged, 
especially for low grade breast cancers. Where as most patients with lung cancer relapse within 6 
months to 1 year, breast cancer patients relapse and survival can be prolonged over 15-20 years. 
Obtaining follow up information over such time periods is challenging and costly. Performing 
studies of this kind in a timely fashion require the availability of tissue collected decades 
previously. Future goals of this project are to develop collaborations with other institutions that 
have tissue databases with follow up. 
 In summary, using the combination of LCM and MALDI MS, differentially expressed 
proteomic patterns among normal mammary epithelium and breast tumors were found. This 
comparative approach to defining these molecular alterations is expected to help identify 
mechanisms of mammary transformation which may lead to novel strategies for the prevention 
and treatment of breast cancer. Differentially expressed proteins among benign and malignant 
epithelium reflect the critical molecular alterations leading to breast cancer development and 
progression. Identification of these unique protein signatures and subsequent identification of 
their component proteins may further identify novel tumor specific markers and potential drug 
targets. 
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Materials and Methods 
Sample collection, tissue microdissection and MALDI MS analysis 
 Primary breast tumors and normal mammary epithelium from reduction mammoplasty 
(RM) specimen were obtained from the Cooperative Human Tissue Network (CHTN). All tissues 
were snap-frozen in liquid nitrogen immediately following removal from the patient. An H&E 
stained section of each tissue sample was examined to select appropriate areas for LCM. The 
specific cells of interest were microdissected by a board-certified pathologist (Melinda Sanders, 
M.D.).  
Choosing a reliable normal control was a critical component of this analysis. We decided 
to use normal mammary epithelium from reduction mammoplasty specimens as our normal 
population for three reasons.  First, these samples are more likely to represent truly normal 
epithelium as these women do not have breast carcinoma or have a history of breast carcinoma.  
Second, it has been shown that histologically normal appearing breast tissue adjacent to tumor but 
not distant to the tumor can have genetic abnormalities identical to those seen in the 
corresponding tumor [124]. These results may truly represent early stages of neoplastic 
transformation in apparently normal tissue but is more likely Pagetoid spread, the spread of 
neoplastic cells in a single cell fashion (a well-known phenomenon to practicing pathologists), 
into adjacent normal ducts and lobular units.  Third, the consistent availability of large numbers 
of reduction mammoplasty specimens from all the procurement centers makes this population a 
robust reference group. 
MALDI-TOF MS was performed directly on the LCM acquired cells using the procedure 
described in Chapter II. Depending on the size of the lesion, 400 to 2000 cells were obtained from 
each sample. Mass spectra were acquired in the liner positive ion mode under optimized delayed 
extraction conditions using a Voyager DE-STR MALDI mass spectrometer with a 337 nm 
nitrogen laser (Applied Biosystems). The instrument settings were as follows: accelerating 
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voltage 25 kV, 91% grid voltage, 150 ns delay time, and 0.05% guide wire voltage. A total of 750 
laser shots were averaged to create a single spectrum from the captured cells. The m/z range of 
the mass spectra was from 2,000 to 70,000. 
 
Data processing and Statistical Analysis 
 The spectra were internally calibrated using previously identified proteins that are 
commonly present in the spectra, such as ubiquitin (8565.8 Da), 40 ribosomal S30 protein 
(6648.8 Da), macrophage inhibitory factor (12345.5 Da) and calmodulin (16792.5 Da). Mass 
spectra were then baseline corrected, smoothed, and normalized and then combined to create a 
single spectrum for each sample type.  Mass windows (bins) which can identify the same peaks 
across multiple spectra were generated. Peaks were aligned across samples and these optimal bins 
were used to define individual protein/peptide peaks within a large data set for statistical analysis.  
Use of this binning technique is preferable to defining variables at each individual mass unit 
because it accounts for nonlinear shifts of the mass-to-charge (m/z) values for a given protein 
between samples. 
 The statistical analyses for these comparisons involved the following steps: (1) selection 
of  differentially expressed peaks among specimen classes which served as statistically significant 
discriminators of the compared groups, (2) generation of class prediction models based upon the 
Weighted Flexible Compound Covariate Method (WFCCM) to verify if the selected proteins 
have statistically significant predictive power on the study subjects, and (3) employment of an 
agglomerative hierarchical clustering algorithm to investigate expression patterns among the 
statistically significant discriminator proteins as well as the biologic status.  
 Using the permutation t test, modified info score method (InfoScore), significance 
analysis of microarrays (SAM), weighted gene analysis, Fisher’s exact test, and the Wilcoxon 
rank sum test, the most significant m/z species with different levels of expression among the 
 
 
 
117
groups were selected. The cut off points for each method were p < 0.0001, 0, 3.5, 2, p < 0.0001 
and p < 0.0001, respectively. Protein markers were included in the final list if they met at least 3 
of these selection criteria.  The misclassification rate was estimated using the leave-one-out cross-
validated class prediction method.  An agglomerative hierarchical clustering algorithm was 
employed to investigate patterns among the statistically significant discriminator proteins.   
 
Protein identification 
 Protein extracts were prepared using 5 x 5 mm3 portions of mammary tumor tissue in 
extraction buffer (0.25 M sucrose, 0.01 M Tris-HCl and 0.1 mM phenylmethanesulfonyl fluoride; 
Sigma), homogenized with a Dual homogenizer and centrifuged 3 times (10 min at 680 g, 10 min 
at 10,000 g and 1 hr at 100,000 g), each time transferring the soluble fraction to a new tube.  The 
final fraction was separated over a C8 column (208TP54, Vydac, Hesperia, CA, USA) at 40°C 
using a Waters Alliance HPLC system (Milford, MA, USA). Solvent A was 0.1% trifluoroacetic 
acid (TFA) in water and solvent B was 0.085% TFA in acetonitrile. A flow rate of 1ml/min was 
used starting at  5% solvent B for 5 min, followed by a series of gradients: 5% to 25% B in 5 min, 
25% to 60% B over 50 min, 60% to 95% B over 10 min.  Collection ended with a final hold at 
95% B for 10 min. The HPLC fractions were collected every minute with individual fractions 
monitored by MALDI-TOF MS. The fractions were then completely dried using Thermo Quest 
Savant Speedvac (Holbrook, NY, USA). Dried HPLC fractions were reconstituted in 10 µl of 
5/5/0.3, v/v/v, acetonitrile/water/TFA and analyzed by MALDI-TOF MS. Fractions containing 
proteins of interest were digested with trypsin for identification. The samples were re-lyophilized 
and reconstituted with 10 microliters of 0.4 M ammonium hydrogen carbonate (EM Science).  
These fractions were reduced in incubation with 5 µl of 45 mM dithiothreitol (Sigma) at 60°C for 
15 min, followed by alkylation with 5 µl of 100 mM iodoacetamide (Sigma) in the dark for 15 
min. For protein digestion, the samples were trypsinized (1 µl of 1 µM bovine sequencing grade 
 
 
 
118
trypsin, Promega) for 4 hrs at 37°C. The tryptic fragments were subjected to LC-MS/MS analysis 
using a ThermoFinnigan LTQ mass spectrometer (San Jose, CA, USA). Two microliter samples 
were loaded into a 100 µm i.d. self-packed micro-capillary reverse phase column packed with 
Monitor C18 -Spherical Silica from Column Engineering Inc (Ontario, CA, USA). The mobile 
phase A was 0.1% formic acid in water and phase B was 0.1% formic acid in acetonitrile. The 
gradient for mobile phase B started at 0% for 3 min, to 5% in 2 min, to 50% in 45 min, and to 
90% in 5 min. The flow rate at the source was 700 nl /min. The tandem mass spectra were used to 
search the National Center for Biotechnology Information (NCBI) human protein database using 
the SEQUEST algorithm [27].  
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